<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2025//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_250101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">37878462</PMID><DateCompleted><Year>2024</Year><Month>01</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>67</Volume><Issue>2</Issue><PubDate><Year>2024</Year><Month>Feb</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Sex-Based Differences in IBD Surgical Outcomes.</ArticleTitle><Pagination><StartPage>246</StartPage><EndPage>253</EndPage><MedlinePgn>246-253</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002984</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Although there are discrepancies in the development and progression of IBD based on biologic sex, little is known about differences in postoperative outcomes between men and women undergoing surgery for this condition.</AbstractText><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To compare rates of anastomotic leaks, wound complications, and serious adverse events between men and women undergoing surgery for IBD.</AbstractText><AbstractText Label="DESIGN" NlmCategory="METHODS">This was a retrospective cohort study.</AbstractText><AbstractText Label="SETTINGS" NlmCategory="METHODS">Data were obtained from the American College of Surgeons National Surgical Quality Improvement Program IBD Collaborative database, which includes 15 high-volume IBD surgery centers.</AbstractText><AbstractText Label="PATIENTS" NlmCategory="METHODS">All adult patients undergoing surgery for IBD were included. Participants with missing data for exposure or outcome variables were excluded.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES" NlmCategory="METHODS">Rates of anastomotic leaks, wound complications, and serious adverse events were compared between women and men.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">A total of 3143 patients were included. There was a significant association between sex and BMI, IBD type, and preoperative medication use. Women had decreased odds of serious adverse events compared to men (OR 0.73; 95% CI, 0.55-0.96), but there was no significant association between sex and anastomotic leaks or wound complications. IBD type was found to be an effect measure modifier of the relationship between sex and serious adverse events. Among patients with ulcerative colitis, women had a 54% decrease in the odds of serious adverse events compared to men, whereas there was no significant difference between women and men with Crohn's disease.</AbstractText><AbstractText Label="LIMITATIONS" NlmCategory="CONCLUSIONS">This study was limited by capturing only 30 days of postoperative outcomes.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Women undergoing surgery for ulcerative colitis had decreased odds of serious adverse events compared to men. Understanding sex-based differences in outcomes allows clinicians to make patient-centered decisions regarding surgical planning and perioperative management for patients with IBD. See Video Abstract .</AbstractText><AbstractText Label="DIFERENCIAS BASADAS EN EL SEXO EN LOS RESULTADOS QUIRRGICOS DE LA ENFERMEDAD INFLAMATORIA INTESTINAL" NlmCategory="UNASSIGNED">ANTECEDENTES:Aunque existen discrepancias en el desarrollo y la progresi&#xf3;n de la enfermedad inflamatoria intestinal seg&#xfa;n el sexo biol&#xf3;gico, se sabe poco sobre las diferencias en los resultados postoperatorios entre hombres y mujeres sometidos a cirug&#xed;a por esta afecci&#xf3;n.OBJETIVO:Nuestro objetivo fue comparar las tasas de fugas anastom&#xf3;ticas, complicaciones de las heridas y eventos adversos graves entre hombres y mujeres sometidos a cirug&#xed;a por enfermedad inflamatoria intestinal.DISE&#xd1;O:Este fue un estudio de cohorte retrospectivo.AJUSTES:Los datos se obtuvieron de la base de datos del Programa Nacional de Mejora de la Calidad Quir&#xfa;rgica del Colegio Americano de Cirujanos para la Enfermedad Inflamatoria Intestinal, que incluye 15 centros de cirug&#xed;a de enfermedad inflamatoria intestinal de alto volumen.PACIENTES:Se incluyeron todos los pacientes adultos sometidos a cirug&#xed;a por enfermedad inflamatoria intestinal. Se excluyeron los sujetos a los que les faltaban datos sobre exposici&#xf3;n o variables de resultado.PRINCIPALES MEDIDAS DE RESULTADO:Se compararon las tasas de fugas anastom&#xf3;ticas, complicaciones de las heridas y eventos adversos graves entre mujeres y hombres.RESULTADOS:Se incluyeron un total de 3.143 pacientes. Hubo una asociaci&#xf3;n significativa entre el sexo y el &#xed;ndice de masa corporal, el tipo de enfermedad inflamatoria intestinal y el uso de medicaci&#xf3;n preoperatoria. Las mujeres tuvieron menores probabilidades de sufrir eventos adversos graves en comparaci&#xf3;n con los hombres (OR = 0,73; IC del 95 %: 0,55 a 0,96), pero no hubo una relacion significativa entre el sexo y las fugas anastom&#xf3;ticas o las complicaciones de las heridas. Se encontr&#xf3; que el tipo de enfermedad inflamatoria intestinal era un modificador de la medida del efecto de la relaci&#xf3;n entre el sexo y los eventos adversos graves. Entre los pacientes con colitis ulcerosa, las mujeres tuvieron una disminuci&#xf3;n del 54 % en las probabilidades de sufrir eventos adversos graves en comparaci&#xf3;n con los hombres, mientras que no hubo diferencias significativas entre mujeres y hombres con enfermedad de Crohn.LIMITACIONES:Este estudio estuvo limitado al capturar solo 30 d&#xed;as de resultados posoperatorios.CONCLUSIONES:Las mujeres sometidas a cirug&#xed;a por colitis ulcerosa tuvieron menores probabilidades de sufrir eventos adversos graves en comparaci&#xf3;n con los hombres. Comprender las diferencias en los resultados basadas en el sexo permite a los m&#xe9;dicos tomar decisiones centradas en el paciente con respecto a la planificaci&#xf3;n quir&#xfa;rgica y el manejo perioperatorio de los pacientes con enfermedad inflamatoria intestinal. (Traducci&#xf3;n-Dr Yolanda Colorado).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sundel</LastName><ForeName>Margaret H</ForeName><Initials>MH</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Maryland, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Newland</LastName><ForeName>John J</ForeName><Initials>JJ</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Maryland, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Blackburn</LastName><ForeName>Kyle W</ForeName><Initials>KW</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Maryland, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vesselinov</LastName><ForeName>Roumen M</ForeName><Initials>RM</Initials><AffiliationInfo><Affiliation>Department of Epidemiology and Public Health, University of Maryland, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Eisenstein</LastName><ForeName>Samuel</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of California San Diego, San Diego, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bafford</LastName><ForeName>Andrea C</ForeName><Initials>AC</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Maryland, Baltimore, Maryland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>NSQIP-IBD Collaborative</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>R33 CA094304</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant><Grant><GrantID>T32 DK067872</GrantID><Acronym>DK</Acronym><Agency>NIDDK NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>10</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003093" MajorTopicYN="Y">Colitis, Ulcerative</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D057868" MajorTopicYN="N">Anastomotic Leak</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="ANTECEDENTES:">Aunque existen discrepancias en el desarrollo y la progresi&#xf3;n de la enfermedad inflamatoria intestinal seg&#xfa;n el sexo biol&#xf3;gico, se sabe poco sobre las diferencias en los resultados posoperatorios entre hombres y mujeres sometidos a cirug&#xed;a por esta afecci&#xf3;n.</AbstractText><AbstractText Label="OBJETIVO:">Nuestro objetivo fue comparar las tasas de fugas anastom&#xf3;ticas, complicaciones de las heridas y eventos adversos graves entre hombres y mujeres sometidos a cirug&#xed;a por enfermedad inflamatoria intestinal.</AbstractText><AbstractText Label="DISE&#xd1;O:">Este fue un estudio de cohorte retrospectivo.</AbstractText><AbstractText Label="AJUSTES:">Los datos se obtuvieron de la base de datos colaborativa del Programa Nacional de Mejora de la Calidad Quir&#xfa;rgica del Colegio Americano de Cirujanos para la Enfermedad Inflamatoria Intestinal, que incluye 15 centros de cirug&#xed;a de enfermedad inflamatoria intestinal de alto volumen.</AbstractText><AbstractText Label="PACIENTES:">Se incluyeron todos los pacientes adultos sometidos a cirug&#xed;a por enfermedad inflamatoria intestinal. Se excluyeron los sujetos a los que les faltaban datos sobre exposici&#xf3;n o variables de resultado.</AbstractText><AbstractText Label="PRINCIPALES MEDIDAS DE RESULTADO:">Se compararon las tasas de fugas anastom&#xf3;ticas, complicaciones de las heridas y eventos adversos graves entre mujeres y hombres.</AbstractText><AbstractText Label="RESULTADOS:">Se incluyeron un total de 3.143 pacientes. Hubo una asociaci&#xf3;n significativa entre el sexo y el &#xed;ndice de masa corporal, el tipo de enfermedad inflamatoria intestinal y el uso de medicaci&#xf3;n preoperatoria. Las mujeres tuvieron menores probabilidades de sufrir eventos adversos graves en comparaci&#xf3;n con los hombres (OR = 0,73; IC del 95 %: 0,55 a 0,96), pero no hubo una asociaci&#xf3;n significativa entre el sexo y las fugas anastom&#xf3;ticas o las complicaciones de las heridas. Se encontr&#xf3; que el tipo de enfermedad inflamatoria intestinal era un modificador de la medida del efecto de la relaci&#xf3;n entre el sexo y los eventos adversos graves. Entre los pacientes con colitis ulcerosa, las mujeres tuvieron una disminuci&#xf3;n del 54 % en las probabilidades de sufrir eventos adversos graves en comparaci&#xf3;n con los hombres, mientras que no hubo diferencias significativas entre mujeres y hombres con enfermedad de Crohn.</AbstractText><AbstractText Label="LIMITACIONES:">Este estudio estuvo limitado al capturar solo 30 d&#xed;as de resultados posoperatorios.</AbstractText><AbstractText Label="CONCLUSIONES:">Las mujeres sometidas a cirug&#xed;a por colitis ulcerosa tuvieron menores probabilidades de sufrir eventos adversos graves en comparaci&#xf3;n con los hombres. Comprender las diferencias en los resultados basadas en el sexo permite a los m&#xe9;dicos tomar decisiones centradas en el paciente con respecto a la planificaci&#xf3;n quir&#xfa;rgica y el manejo perioperatorio de los pacientes con enfermedad inflamatoria intestinal. Consulte Video Resumen en http://links.lww.com/DCR/Bxxx. <i>(Pre-proofed version)</i></AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2023.</CopyrightInformation></OtherAbstract><InvestigatorList><Investigator ValidYN="Y"><LastName>Eisenstein</LastName><ForeName>Samuel</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ramamoorthy</LastName><ForeName>Sonia</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hilbert</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Du</LastName><ForeName>Austin</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Department of Colon &amp; Rectal Surgery, Cleveland Clinic, 9500 Euclid Ave A30, Cleveland, OH 44195.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Hull</LastName><ForeName>Tracy</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holubar</LastName><ForeName>Stefan</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Jia</LastName><ForeName>Xue</ForeName><Initials>X</Initials></Investigator><Investigator ValidYN="Y"><LastName>Anzlovar</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bohne</LastName><ForeName>Sue</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Surgery, Baylor University Medical Center, 3409 Worth St, Worth Tower, Suite 600, Dallas, TX 75246.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Fichera</LastName><ForeName>Alessandro</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Aguilar</LastName><ForeName>Debbie</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mueller</LastName><ForeName>Martha</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Colorectal Surgery Program, Massachusetts General Hospital, 15 Parkman St, Boston, MA 02114-3117.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Riccardi</LastName><ForeName>Rocco</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Bordeianou</LastName><ForeName>Liliana</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kunitake</LastName><ForeName>Hiroko</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Antonelli</LastName><ForeName>Donna</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Swierzewski</LastName><ForeName>Kathy</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Devaney</LastName><ForeName>Lynn</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Stanford Health Care, 500 Pasteur Dr, Palo Alto, CA 94304.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Kin</LastName><ForeName>Cindy</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Spain</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hyke</LastName><ForeName>Roxanne</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>De Leon</LastName><ForeName>Elmer</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Torbela</LastName><ForeName>Aimee</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of General Surgery, Albany Medical Center, 50 New Scotland Ave MC-193, 5th Floor, Albany, NY 12208.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Lee</LastName><ForeName>Edward</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Valerian</LastName><ForeName>Brian</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Keenan</LastName><ForeName>Megan</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goyette</LastName><ForeName>Andrea</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Shapiro Building, 3rd Floor, Boston, MA 02215-5400.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Messaris</LastName><ForeName>Evangelos</ForeName><Initials>E</Initials></Investigator><Investigator ValidYN="Y"><LastName>Whyte</LastName><ForeName>Richard</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ward</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cotter</LastName><ForeName>Mary Beth</ForeName><Initials>MB</Initials><AffiliationInfo><Affiliation>Division of Colon and Rectal Surgery, Lahey Hospital and Medical Center, 41 Mall Rd, Burlington, MA 01805.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Saraidaridis</LastName><ForeName>Julia</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lewis</LastName><ForeName>W David</ForeName><Initials>WD</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sansone</LastName><ForeName>Mary</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Crawford</LastName><ForeName>Lynne</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>Department of Surgery, Penn State Health, 200 Campus Dr, Suite 3100 Hershey, PA 17033.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Deutsch</LastName><ForeName>Michael</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Scow</LastName><ForeName>Jeffrey</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Huggins</LastName><ForeName>Pam</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Surgery, Emory University School of Medicine, Room B206, 1364 Clifton Rd, NE, Atlanta, GA 30322.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Shaffer</LastName><ForeName>Virginia</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sharma</LastName><ForeName>Joe</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sitafalwalla</LastName><ForeName>Shamsah</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Surgery, Washington University School of Medicine in St Louis, 660 S Euclid Ave, St Louis, MO 63110.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Smith</LastName><ForeName>Radhika</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mutch</LastName><ForeName>Matthew</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hall</LastName><ForeName>Bruce</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hirbe</LastName><ForeName>Mitzi</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Batten</LastName><ForeName>JoAnn</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Surgery, Box 1259, Mount Sinai Medical Center, One Gustave L. Levy Place, NY, NY 10029.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Steinhagen</LastName><ForeName>Randolph</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Khaitov</LastName><ForeName>Sergey</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sylla</LastName><ForeName>Patricia</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Divino</LastName><ForeName>Celia</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Miller</LastName><ForeName>Reba</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Chicago, 5841 S Maryland Ave, MC 5095, Chicago, IL 60637.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Olortegui</LastName><ForeName>Kinga Skowron</ForeName><Initials>KS</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hyman</LastName><ForeName>Neil</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Prachand</LastName><ForeName>Vivek</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Sullivan</LastName><ForeName>Sue</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pullins</LastName><ForeName>Lorice</ForeName><Initials>L</Initials></Investigator><Investigator ValidYN="Y"><LastName>Barc</LastName><ForeName>Carmen</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Iowa Hospitals and Clinics, 200 Hawkins Dr, Iowa City, IA 52242.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Hrabe</LastName><ForeName>Jennifer</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kapadia</LastName><ForeName>Muneera</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Belding-Schmitt</LastName><ForeName>Mary</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Iowa, Iowa City, IA 52242.</Affiliation></AffiliationInfo></Investigator><Investigator ValidYN="Y"><LastName>Yoo</LastName><ForeName>James</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Goldberg</LastName><ForeName>Joel</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Akinbami</LastName><ForeName>Felix</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Steinberg</LastName><ForeName>Jill</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Department of Surgery, Brigham and Women's Hospital, 75 Francis St, Boston, MA 02115.</Affiliation></AffiliationInfo></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>1</Month><Day>12</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>10</Month><Day>25</Day><Hour>18</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>10</Month><Day>25</Day><Hour>12</Hour><Minute>33</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2025</Year><Month>2</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">37878462</ArticleId><ArticleId IdType="mid">NIHMS1937949</ArticleId><ArticleId IdType="pmc">PMC10843447</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002984</ArticleId><ArticleId IdType="pii">00003453-202402000-00009</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Greuter T, Manser C, Pittet V, et al. Gender differences in inflammatory bowel disease. Digestion. 2020;101 Suppl 1:98&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">31995797</ArticleId></ArticleIdList></Reference><Reference><Citation>Shah SC, Khalili H, Gower-Rousseau C, et al. Sex-based differences in incidence of inflammatory bowel diseases-pooled analysis of population-based studies from Western countries. Gastroenterology. 2018;155:1079&#x2013;1089.e3.</Citation><ArticleIdList><ArticleId IdType="pubmed">29958857</ArticleId></ArticleIdList></Reference><Reference><Citation>Prideaux L, Kamm MA, de Cruz PP, et al. Inflammatory bowel disease in Asia: a systematic review. J Gastroenterol Hepatol. 2012;27:1266&#x2013;1280.</Citation><ArticleIdList><ArticleId IdType="pubmed">22497584</ArticleId></ArticleIdList></Reference><Reference><Citation>Mazor Y, Maza I, Kaufman E, et al. Prediction of disease complication occurrence in Crohn&#x2019;s disease using phenotype and genotype parameters at diagnosis. J Crohn&#x2019;s Colitis. 2011;5:592&#x2013;597.</Citation><ArticleIdList><ArticleId IdType="pubmed">22115380</ArticleId></ArticleIdList></Reference><Reference><Citation>Walldorf J, Krummenerl A, Engler K, et al. Health care for osteoporosis in inflammatory bowel disease: unmet needs in care of male patients? J Crohn&#x2019;s Colitis. 2013;7:901&#x2013;907.</Citation><ArticleIdList><ArticleId IdType="pubmed">23333038</ArticleId></ArticleIdList></Reference><Reference><Citation>Severs M, Spekhorst LM, Mangen MJJ, et al. Sex-related differences in patients with inflammatory bowel disease: results of 2 prospective cohort studies. Inflamm Bowel Dis. 2018;24:1298&#x2013;1306.</Citation><ArticleIdList><ArticleId IdType="pubmed">29688413</ArticleId></ArticleIdList></Reference><Reference><Citation>Ramos LR, Sachar DB, DiMaio CJ, Colombel JF, Torres J. Inflammatory bowel disease and pancreatitis: a review. J Crohn&#x2019;s Colitis. 2016;10:95&#x2013;104.</Citation><ArticleIdList><ArticleId IdType="pubmed">26351384</ArticleId></ArticleIdList></Reference><Reference><Citation>S&#xf6;derlund S, Granath F, Brostr&#xf6;m O, et al. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Gastroenterology. 2010;138:1697&#x2013;1703.e2.</Citation><ArticleIdList><ArticleId IdType="pubmed">20167217</ArticleId></ArticleIdList></Reference><Reference><Citation>Mudireddy P, Scott F, Feathers A, Lichtenstein GR. Inflammatory bowel disease: predictors and causes of early and late hospital readmissions. Inflamm Bowel Dis. 2017;23:1832&#x2013;1839.</Citation><ArticleIdList><ArticleId IdType="pubmed">28858068</ArticleId></ArticleIdList></Reference><Reference><Citation>Billioud V, Sandborn WJ, Peyrin-Biroulet L. Loss of response and need for adalimumab dose intensification in Crohn&#x2019;s disease: A systematic review. Am J Gastroenterol. 2011;106:674&#x2013;684.</Citation><ArticleIdList><ArticleId IdType="pubmed">21407178</ArticleId></ArticleIdList></Reference><Reference><Citation>Hofer B, B&#xf6;ttger T, Hernandez-Richter T, Seifert JK, Junginger T. The impact of clinical types of disease manifestation on the risk of early postoperative recurrence in Crohn&#x2019;s disease. Hepatogastroenterology. 2001;48:152&#x2013;155. https://europepmc.org/article/med/11268954. Accessed February 9, 2022.
</Citation><ArticleIdList><ArticleId IdType="pubmed">11268954</ArticleId></ArticleIdList></Reference><Reference><Citation>Peyrin-Biroulet L, Harmsen WS, Tremaine WJ, Zinsmeister AR, Sandborn WJ. Loftus E v. Surgery in a population-based cohort of Crohn&#x2019;s disease from Olmsted County, Minnesota (1970&#x2013;2004). Am J Gastroenterol. 2012;107:1693&#x2013;1701.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3572861</ArticleId><ArticleId IdType="pubmed">22945286</ArticleId></ArticleIdList></Reference><Reference><Citation>Samuel S, Ingle SB, Dhillon S, et al. Cumulative incidence and risk factors for hospitalization and surgery in a population-based cohort of ulcerative colitis. Inflamm Bowel Dis. 2013;19:1858&#x2013;1866.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4526131</ArticleId><ArticleId IdType="pubmed">23660997</ArticleId></ArticleIdList></Reference><Reference><Citation>Targownik LE, Singh H, Nugent Z, Bernstein CN. The epidemiology of colectomy in ulcerative colitis: results from a population-based cohort. Am J Gastroenterol. 2012;107:1228&#x2013;1235.</Citation><ArticleIdList><ArticleId IdType="pubmed">22613902</ArticleId></ArticleIdList></Reference><Reference><Citation>Li Y, Zhu W. Common Complications of Surgery for Crohn&#x2019;s Disease and Ulcerative Colitis. In: Bo Shen, ed. Interventional Inflammatory Bowel Disease: Endoscopic Management and Treatment of Complications. Academic Press; 2018:273&#x2013;286.</Citation></Reference><Reference><Citation>Randall J, Singh B, Warren BF, Travis SPL, Mortensen NJ, George BD. Delayed surgery for acute severe colitis is associated with increased risk of postoperative complications. Br J Surg. 2010;97:404&#x2013;409.</Citation><ArticleIdList><ArticleId IdType="pubmed">20101648</ArticleId></ArticleIdList></Reference><Reference><Citation>Kasparek MS, Bruckmeier A, Beigel F, et al. Infliximab does not affect postoperative complication rates in Crohn&#x2019;s patients undergoing abdominal surgery. Inflamm Bowel Dis. 2012;18:1207&#x2013;1213.</Citation><ArticleIdList><ArticleId IdType="pubmed">21928373</ArticleId></ArticleIdList></Reference><Reference><Citation>Waterland P, Athanasiou T, Patel H. Post-operative abdominal complications in Crohn&#x2019;s disease in the biological era: systematic review and meta-analysis. World J Gastrointest Surg. 2016;8:274.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4807329</ArticleId><ArticleId IdType="pubmed">27022455</ArticleId></ArticleIdList></Reference><Reference><Citation>Peyrin-Biroulet L, Germain A, Patel AS, Lindsay JO. Systematic review: outcomes and post-operative complications following colectomy for ulcerative colitis. Aliment Pharmacol Ther. 2016;44:807&#x2013;816.</Citation><ArticleIdList><ArticleId IdType="pubmed">27534519</ArticleId></ArticleIdList></Reference><Reference><Citation>Rottoli M, Remzi FH, Shen B, Kiran RP. Gender of the patient may influence perioperative and long-term complications after restorative proctocolectomy. Colorectal Dis. 2012;14:336&#x2013;341.</Citation><ArticleIdList><ArticleId IdType="pubmed">21689322</ArticleId></ArticleIdList></Reference><Reference><Citation>Luo WY, Holubar SD, Bordeianou L, et al. Better characterization of operation for ulcerative colitis through the National surgical quality improvement program: A 2-year audit of NSQIP-IBD. Am J Surg. 2021;221:174&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7736277</ArticleId><ArticleId IdType="pubmed">32928540</ArticleId></ArticleIdList></Reference><Reference><Citation>Weir CB, Jan A. BMI Classification Percentile And Cut Off Points. StatPearls. Published online June 29, 2021. Accessed July 23, 2022.</Citation><ArticleIdList><ArticleId IdType="pubmed">31082114</ArticleId></ArticleIdList></Reference><Reference><Citation>Knapp BM, Botros M, Sing DC, Curry EJ, Eichinger JK, Li X. Sex differences in complications and readmission rates following shoulder arthroplasty in the United States. JSES Int. 2020;4:95&#x2013;99.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7075761</ArticleId><ArticleId IdType="pubmed">32195469</ArticleId></ArticleIdList></Reference><Reference><Citation>Swaminathan RV, Feldman DN, Pashun RA, et al. Gender differences in in-hospital outcomes after coronary artery bypass grafting. Am J Cardiol. 2016;118:362&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">27269585</ArticleId></ArticleIdList></Reference><Reference><Citation>He JW, Sun LY, Wijeysundera D, Vogt K, Jones PM. Patient sex and postoperative outcomes after inpatient intraabdominal surgery: a population-based retrospective cohort study. Anesthesiology. 2022;136:577&#x2013;587.</Citation><ArticleIdList><ArticleId IdType="pubmed">35188547</ArticleId></ArticleIdList></Reference><Reference><Citation>Ziv Y, Fazio VW, Church JM, et al. Stapled ileal pouch anal anastomoses are safer than handsewn anastomoses in patients with ulcerative colitis. Am J Surg. 1996;171:320&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">8615465</ArticleId></ArticleIdList></Reference><Reference><Citation>Jakobson T, Karjagin J, Vipp L, et al. Postoperative complications and mortality after major gastrointestinal surgery. Medicina (B Aires). 2014;50:111&#x2013;117.</Citation><ArticleIdList><ArticleId IdType="pubmed">25172605</ArticleId></ArticleIdList></Reference><Reference><Citation>Ikeuchi H, Nakano H, Uchino M, et al. Safety of one-stage restorative proctocolectomy for ulcerative colitis. Dis Colon Rectum. 2005;48:1550&#x2013;1555.</Citation><ArticleIdList><ArticleId IdType="pubmed">15937613</ArticleId></ArticleIdList></Reference><Reference><Citation>Wagtmans MJ, Verspaget HW, Lamers CBHW, van Hogezand RA. Gender-related differences in the clinical course of Crohn&#x2019;s disease. Am J Gastroenterol. 2001;96:1541&#x2013;1546.</Citation><ArticleIdList><ArticleId IdType="pubmed">11374696</ArticleId></ArticleIdList></Reference><Reference><Citation>Rustgi SD, Kayal M, Shah SC. Sex-based differences in inflammatory bowel diseases: a review. https://doi.org/101177/1756284820915043. 2020;13.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7236567</ArticleId><ArticleId IdType="pubmed">32523620</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertakis KD, Azari R, Helms LJ, et al. Gender differences in the utilization of health care services. J Fam Pract. 2000;49:147&#x2013;152.</Citation><ArticleIdList><ArticleId IdType="pubmed">10718692</ArticleId></ArticleIdList></Reference><Reference><Citation>Pinkhasov RM, Wong J, Kashanian J, et al. Are men shortchanged on health? Perspective on health care utilization and health risk behavior in men and women in the United States. Int J Clin Pract. 2010;64:475&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">20456194</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">36649209</PMID><DateCompleted><Year>2023</Year><Month>10</Month><Day>23</Day></DateCompleted><DateRevised><Year>2025</Year><Month>01</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>11</Issue><PubDate><Year>2023</Year><Month>Nov</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Preoperative CT Indices Predict Nonreach Before IPAA.</ArticleTitle><Pagination><StartPage>1500</StartPage><EndPage>1507</EndPage><MedlinePgn>1500-1507</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002674</ELocationID><Abstract><AbstractText Label="BACKGROUND">IPAA aims to restore continence to patients after total proctocolectomy. However, some patients have inadequate small-bowel mesenteric length to achieve reconstruction. No preoperative risk stratification tools of native anatomy exist.</AbstractText><AbstractText Label="OBJECTIVE">We report CT-guided measurements of anatomic landmarks to predict nonreach before IPAA.</AbstractText><AbstractText Label="DESIGN">This is a single-institution retrospective analysis of a prospective database.</AbstractText><AbstractText Label="SETTING">This study was conducted at Cedars-Sinai between January 2007 and December 2021.</AbstractText><AbstractText Label="PATIENTS">Patients with IBD undergoing a 2- or 3-stage IPAA with a preoperative abdominal CT using either an enterography protocol or IV contrast sufficient to visualize mesenteric vasculature were included in the study. CT mesenteric indices were assessed, including total length (representing length required for the pouch to reach the anal canal), mesenteric length (inherent length of small-bowel mesentery), and mobilization length (the difference between total length and mesenteric length).</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The primary outcome was IPAA nonreach. The secondary outcomes were association of clinical variables and CT mesenteric indices.</AbstractText><AbstractText Label="RESULTS">Six of 59 patients (10%) experienced nonreach. Mobilization length was longer in the nonreach group by 5.8&#x2009;cm ( p = 0.01), and mesenteric length was shorter by 3.5&#x2009;cm ( p = 0.04). Mobilization length &#x2265;17&#x2009;cm provided 100% sensitivity and 69% specificity (OR 1.46, area under the curve 0.84, p = 0.004) for nonreach. Similarly, a mesenteric length &lt;14.6&#x2009;cm demonstrated 100% sensitivity and 49% specificity for IPAA nonreach (area under the curve 0.75, p = 0.03).</AbstractText><AbstractText Label="LIMITATIONS">The retrospective nature of the study precluded a standardized imaging protocol. External validation will be required because of the small sample size.</AbstractText><AbstractText Label="CONCLUSIONS">CT-based measurements of length, specifically mesenteric and mobilization length, predict nonreach before IPAA. This method is noninvasive, readily available, and may be useful for preoperative patient counseling and operative planning. See Video Abstract at http://links.lww.com/DCR/C140 .</AbstractText><AbstractText Label="LOS NDICES DE TOMOGRAFA COMPUTARIZADA PREOPERATORIA PREDICEN LA AUSENCIA DE ALCANCE ANTES DE LA ANASTOMOSIS DEL RESERVORIO ILEALANAL">ANTECEDENTES:La anastomosis del reservorio ileoanal tiene como objetivo restaurar la continencia en los pacientes despu&#xe9;s de una proctocolectom&#xed;a total. Sin embargo, algunos pacientes tienen una longitud mesent&#xe9;rica del intestino delgado inadecuada para lograr la reconstrucci&#xf3;n. No existen herramientas de estratificaci&#xf3;n del riesgo preoperatorio de la anatom&#xed;a nativa.OBJETIVO:Informamos mediciones guiadas por tomograf&#xed;a computarizada de puntos de referencia anat&#xf3;micos para predecir la falta de alcance antes de la anastomosis ileoanal con reservorio.DISE&#xd1;O:Este es un an&#xe1;lisis retrospectivo de una sola instituci&#xf3;n de una base de datos prospectiva.AJUSTE:Este estudio se realiz&#xf3; en Cedars-Sinai entre Enero de 2007 y Diciembre de 2021.PACIENTES:Pacientes con enfermedad inflamatoria intestinal que se someten a una anastomosis anal con reservorio ileal en 2 o 3 etapas con una tomograf&#xed;a computarizada abdominal preoperatoria utilizando un protocolo de enterograf&#xed;a o contraste intravenoso suficiente para visualizar la vasculatura mesent&#xe9;rica. Se evaluaron los &#xed;ndices mesent&#xe9;ricos de tomograf&#xed;a computarizada, incluida la longitud total (que representa la longitud requerida para que la bolsa alcance el canal anal), la longitud mesent&#xe9;rica (longitud inherente del mesenterio del intestino delgado) y la longitud de movilizaci&#xf3;n (la diferencia entre la longitud total y la longitud mesent&#xe9;rica).PRINCIPALES MEDIDAS DE RESULTADO:El resultado primario fue falta de alcance de la anastomosis del reservorio ileoanal. Los resultados secundarios fueron la asociaci&#xf3;n de variables cl&#xed;nicas y los &#xed;ndices mesent&#xe9;ricos de tomograf&#xed;a computarizada.RESULTADOS:Seis de 59 (10%) pacientes experimentaron falta de alcance. La longitud de movilizaci&#xf3;n fue mayor en el grupo sin alcance en 5,8&#x2009;cm ( p = 0,01) y la longitud mesent&#xe9;rica fue menor en 3,5&#x2009;cm ( p = 0,04). La longitud de movilizaci&#xf3;n &#x2265;17&#x2009;cm proporcion&#xf3; una sensibilidad del 100% y una especificidad del 69% (OR 1,46, AUC 0,84, p = 0,004) para la falta de alcance. De manera similar, una longitud mesent&#xe9;rica &lt;14,6&#x2009;cm demostr&#xf3; una sensibilidad del 100% y una especificidad del 49% para la falta de alcance de la anastomosis del reservorio ileoanal (AUC 0,75, p = 0,03).LIMITACIONES:La naturaleza retrospectiva del estudio impidi&#xf3; un protocolo de im&#xe1;genes estandarizado. Se requerir&#xe1; una validaci&#xf3;n externa debido al peque&#xf1;o tama&#xf1;o de la muestra.CONCLUSIONES:Las mediciones de longitud basadas en tomograf&#xed;a computarizada, espec&#xed;ficamente la longitud mesent&#xe9;rica y de movilizaci&#xf3;n, predicen la falta de alcance antes de la anastomosis anal con bolsa ileo. Este m&#xe9;todo no es invasivo, est&#xe1; f&#xe1;cilmente disponible y puede ser &#xfa;til para el asesoramiento preoperatorio del paciente y la planificaci&#xf3;n quir&#xfa;rgica. Consulte el Video Resumen en https://links.lww.com/DCR/C140 . (Traducci&#xf3;n-Dr. Yesenia Rojas-Khalil ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2023.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Adams</LastName><ForeName>Evan D</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Department of General Surgery, Cedars-Sinai Medical Center, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lansky</LastName><ForeName>Charlotte A</ForeName><Initials>CA</Initials><AffiliationInfo><Affiliation>Department of Radiology, Cedars-Sinai Medical Center, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kallman</LastName><ForeName>Cindy E</ForeName><Initials>CE</Initials><AffiliationInfo><Affiliation>Department of Radiology, Cedars-Sinai Medical Center, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zaghiyan</LastName><ForeName>Karen N</ForeName><Initials>KN</Initials><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Cedars-Sinai Medical Center, Los Angeles, California.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Fleshner</LastName><ForeName>Phillip R</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Division of Colorectal Surgery, Cedars-Sinai Medical Center, Los Angeles, California.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>01</Month><Day>06</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016737" MajorTopicYN="Y">Proctocolectomy, Restorative</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000714" MajorTopicYN="N">Anastomosis, Surgical</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007082" MajorTopicYN="N">Ileum</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014057" MajorTopicYN="N">Tomography, X-Ray Computed</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011183" MajorTopicYN="N">Postoperative Complications</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>10</Month><Day>23</Day><Hour>0</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2023</Year><Month>1</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2023</Year><Month>1</Month><Day>17</Day><Hour>13</Hour><Minute>3</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">36649209</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002674</ArticleId><ArticleId IdType="pii">00003453-202311000-00015</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Parks AG, Nicholls RJ. Proctocolectomy without ileostomy for ulcerative colitis. BMJ. 1978;2:85&#x2013;88.</Citation></Reference><Reference><Citation>Uraiqat AA, Byrne CMD, Phillips RKS. Gaining length in ileal-anal pouch reconstruction: a review. Colorectal Dis. 2007;9:657&#x2013;661.</Citation></Reference><Reference><Citation>Chun HK, Smith LE, Orkin BA. Intraoperative reasons for abandoning ileal pouch-anal anastomosis procedures. Dis Colon Rectum. 1995;38:273&#x2013;275.</Citation></Reference><Reference><Citation>Poh KS, Qureshi S, Hong YK, et al. Multivariate prediction of intraoperative abandonment of ileal pouch anal anastomosis. Dis Colon Rectum. 2020;63:639&#x2013;645.</Citation></Reference><Reference><Citation>Browning SM, Nivatvongs S. Intraoperative abandonment of ileal pouch to anal anastomosis&#x2014;the Mayo Clinic experience. J Am Coll Surg. 1998;186:441&#x2013;445.</Citation></Reference><Reference><Citation>Khasawneh MA, McKenna NP, Abdelsattar ZM, et al. Impact of BMI on ability to successfully create an IPAA. Dis Colon Rectum. 2016;59:1034&#x2013;1038.</Citation></Reference><Reference><Citation>Emoto S, Hata K, Nozawa H, et al. Risk factors for non-reaching of ileal pouch to the anus in laparoscopic restorative proctocolectomy with handsewn anastomosis for ulcerative colitis. Intest Res. 2022;20:313&#x2013;320.</Citation></Reference><Reference><Citation>Ohira G, Miyauchi H, Narushima K, et al. Predicting difficulty in extending the ileal pouch to the anus in restorative proctocolectomy: investigation of a simple predictive method using computed tomography. Colorectal Dis. 2017;19:O34&#x2013;O38.</Citation></Reference><Reference><Citation>Adams E, Lansky CD, Zaghiyan KN, Kallman C, Fleshner PR. Can difficult reach during ileal pouch-anal anastomosis (IPAA)? [ASCRS abstract SP9] Dis Colon Rectum. 2022;65:e383&#x2013;e656.</Citation></Reference><Reference><Citation>Le Q, Melmed G, Dubinsky M, et al. Surgical outcome of ileal pouch-anal anastomosis when used intentionally for well-defined Crohn&#x2019;s disease. Inflamm Bowel Dis. 2013;19:30&#x2013;36.</Citation></Reference><Reference><Citation>Aviran E, Assaf D, Zaghiyan K, Fleshner P. Long-term outcomes and factors predicting outcome of ileal pouch-anal anastomosis when used intentionally for well-defined Crohn&#x2019;s disease. Dis Colon Rectum. 2023;66:700&#x2013;706.</Citation></Reference><Reference><Citation>Lee RH, Efron DT, Tantry U, et al. Inhibition of tumor necrosis factor-&#x3b1; attenuates wound breaking strength in rats. Wound Repair Regen. 2000;8:547&#x2013;553.</Citation></Reference><Reference><Citation>Selvaggi F, Pellino G, Canonico S, Sciaudone G. Effect of preoperative biologic drugs on complications and function after restorative proctocolectomy with primary ileal pouch formation: systematic review and meta-analysis. Inflamm Bowel Dis. 2015;21:79&#x2013;92.</Citation></Reference><Reference><Citation>Punja R, Punja D. Exploration of the coeliac trunk for its morphometry and positional relationships using cadaveric and radiological methods. Transl Res Anat. 2021;24:100116.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35764093</PMID><DateCompleted><Year>2023</Year><Month>03</Month><Day>10</Day></DateCompleted><DateRevised><Year>2023</Year><Month>07</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>4</Issue><PubDate><Year>2023</Year><Month>Apr</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Improved Survival in a Cohort of Patients Aged 75 Years and Older With Fecal Immunochemical Testing-Detected Colorectal Cancer.</ArticleTitle><Pagination><StartPage>511</StartPage><EndPage>520</EndPage><MedlinePgn>511-520</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002409</ELocationID><Abstract><AbstractText Label="BACKGROUND">Fecal immunochemical testing is an accepted form of colorectal cancer screening and is recommended for adults up to the age of 75 years in Canadian guidelines. However, many individuals 75 years and older continue to receive fecal immunochemical testing despite being outside accepted guidelines.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to determine whether patients aged 75 years and older with screen-detected cancer demonstrated improved outcomes and survival compared with patients with non-screen-detected cancer.</AbstractText><AbstractText Label="DESIGN">This is a retrospective population-based cohort study.</AbstractText><AbstractText Label="SETTINGS">Provincial data were collected from the Alberta Cancer Registry and the Alberta Colorectal Cancer Screening Program between November 2013 and 2019.</AbstractText><AbstractText Label="PATIENTS">We identified an aggregated patient cohort aged 75 years and older with a diagnosis of colorectal cancer from November 2013 to November 2019, as well as patients 75 years and older who underwent fecal immunochemical testing within these dates.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">The proportion of screen-detected colorectal cancers was calculated. Surgical intervention, hospital length of stay, postoperative mortality, and overall survival were analyzed.</AbstractText><AbstractText Label="RESULTS">Between November 2013 and 2019, 3586 patients 75 years and older were diagnosed with colorectal cancer; 690 (19%) were "screen-detected." Screen-detected patients were almost 3 times more likely to undergo surgery (OR, 2.83) and had a 36% overall survival benefit (HR, 0.64) compared with non-screen-detected patients, adjusted for other variables such as age, Charlson Comorbidity Index, and stage.</AbstractText><AbstractText Label="LIMITATIONS">The retrospective study design prevents conclusions regarding causation.</AbstractText><AbstractText Label="CONCLUSIONS">Screen detection of colorectal cancer in patients aged 75 years and older is associated with improved overall survival when controlling for other potential confounders. When compared with their non-screen-detected counterparts, these patients have an earlier stage of disease and are more likely to undergo surgical intervention with improved outcomes, irrespective of age. These data may support screening for appropriately selected patients who would otherwise fall outside of current guidelines. See Video Abstract at http://links.lww.com/DCR/B986 .</AbstractText><AbstractText Label="SOBREVIDA MEJORADA EN UNA COHORTE DE PACIENTES DE AOS O MS CON CNCER COLORRECTAL DETECTADOS POR RIF">ANTECEDENTES:La prueba basada en una Reacci&#xf3;n Inmunoqu&#xed;mica Fecal - RIF, es una forma aceptada de detecci&#xf3;n de c&#xe1;ncer colorrectal y esta recomendada en adultos a partir de los 75 a&#xf1;os en las gu&#xed;as canadienses. Sin embargo, muchas personas de 75 a&#xf1;os o m&#xe1;s contin&#xfa;an realiz&#xe1;ndose pruebas inmunoqu&#xed;micas fecales a pesar de estar fuera de las gu&#xed;as aceptadas.OBJETIVO:Poder determinar si los pacientes de 75 a&#xf1;os o m&#xe1;s con detecci&#xf3;n RIF positiva a un c&#xe1;ncer demuestran mejores resultados y sobrevida comparados con los pacientes sin detecci&#xf3;n.DISE&#xd1;O:Estudio de cohortes retrospectivo basado en una poblaci&#xf3;n definida.CONFIGURACI&#xd3;N:Se recopilaron los datos provinciales del Registro de c&#xe1;nceres y del Programa de detecci&#xf3;n de c&#xe1;ncer colorrectal de Alberta, Canada, entre 2013 y 2019.PACIENTES:Identificamos una cohorte agregada de pacientes de 75 a&#xf1;os o m&#xe1;s con diagn&#xf3;stico de c&#xe1;ncer colorrectal desde noviembre de 2013 hasta noviembre de 2019, as&#xed; como pacientes de 75 a&#xf1;os o m&#xe1;s que se sometieron a pruebas inmunoqu&#xed;micas fecales dentro de las fechas mencionadas.PRINCIPALES MEDIDAS DE RESULTADO:Se calcul&#xf3; la proporci&#xf3;n de c&#xe1;nceres colorrectales detectados mediante un cribado. Se analizaron la intervenci&#xf3;n quir&#xfa;rgica, la duraci&#xf3;n de la estad&#xed;a hospitalaria, la mortalidad post-operatoria y la sobrevida global.RESULTADOS:Entre noviembre de 2013 y noviembre 2019, 3586 pacientes de 75 a&#xf1;os o m&#xe1;s, fueron diagnosticados con c&#xe1;ncer colorrectal; 690 (19%) fueron detectados por cribado. Los pacientes detectados mediante el cribado, ten&#xed;an casi tres veces m&#xe1;s probabilidades de someterse a una cirug&#xed;a (Raz&#xf3;n de Probabilidad de 2,83) y beneficiaron de una sobrevida general del 36 % (HR 0,64) comparados con los pacientes sin detectaci&#xf3;n por cribado, corregidos por otras variables como la edad, el &#xed;ndice de comorbilidad de Charlson y el estad&#xed;o del tumor.LIMITACIONES:El dise&#xf1;o retrospective del presente estudio impide obtener conclusiones con respecto a la causalidad.CONCLUSIONES:La detecci&#xf3;n por cribado de c&#xe1;ncer colorrectal en pacientes de 75 a&#xf1;os o m&#xe1;s se asocia con una mejor sobrevida general cuando se controlan los otros posibles factores de confusi&#xf3;n. Comparando con las contrapartes no detectadas por cribado, estos pacientes se encuentran en una etapa m&#xe1;s temprana de la enfermedad y es m&#xe1;s probable que se sometan a una intervenci&#xf3;n quir&#xfa;rgica con mejores resultados, independientemente a la edad. Estos datos pueden respaldar la detecci&#xf3;n de pacientes adecuadamente seleccionados que, de otro modo, quedar&#xed;an fuera de las pautas actuales. Consulte Video Resumen en http://links.lww.com/DCR/B986 . (Traducci&#xf3;n-Dr. Xavier Delgadillo ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Cahill</LastName><ForeName>Caitlin</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Calgary, Calgary, Alberta.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lipson</LastName><ForeName>Mark E</ForeName><Initials>ME</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Calgary, Calgary, Alberta.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Afzal</LastName><ForeName>Arfan R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Faculty of Nursing, University of Calgary, Calgary, Alberta.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maclean</LastName><ForeName>Anthony R</ForeName><Initials>AR</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Calgary, Calgary, Alberta.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wong</LastName><ForeName>Clarence K</ForeName><Initials>CK</Initials><AffiliationInfo><Affiliation>Division of Gastroenterology, Department of Medicine' University of Alberta, Edmonton, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roen</LastName><ForeName>Sharla</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Calgary, Calgary, Alberta.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Buie</LastName><ForeName>W Donald</ForeName><Initials>WD</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Calgary, Calgary, Alberta.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>06</Month><Day>28</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012042" MajorTopicYN="N">Registries</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>6</Month><Day>29</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>3</Month><Day>11</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>6</Month><Day>28</Day><Hour>18</Hour><Minute>52</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35764093</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002409</ArticleId><ArticleId IdType="pii">00003453-202304000-00005</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>CCSA Committee. Canadian Cancer Statistics 2019. Published 2019. Accessed August 14, 2021. cancer.ca/Canadian-Cancer-Statistics-2019-EN .</Citation></Reference><Reference><Citation>American Cancer Society. Cancer Facts &amp; Figures 2020. Published 2020. Accessed August 14, 2021. https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2020/cancer-facts-and-figures-2020.pdf .</Citation></Reference><Reference><Citation>Tong L, Ahn C, Symanski E, Lai D, Du XL. Relative impact of earlier diagnosis and improved treatment on survival for colorectal cancer: a US database study among elderly. Cancer Epidemiol. 2014;38:733&#x2013;740.</Citation></Reference><Reference><Citation>de Neree Tot Babberich MPM, Vermeer NCA, Wouters MWJM, et al. Dutch ColoRectal Audit. Postoperative outcomes of screen-detected vs non-screen-detected colorectal cancer in the Netherlands. JAMA Surg. 2018;153:e183567.</Citation></Reference><Reference><Citation>Hewitson P, Glasziou P, Irwig L, Towler B, Watson E. Screening for colorectal cancer using the faecal occult blood test, hemoccult. Cochrane Database Syst Rev. 2017;2007:CD001216.</Citation></Reference><Reference><Citation>Amri R, Bordeianou LG, Sylla P, Berger DL. Impact of screening colonoscopy on outcomes in colon cancer surgery. JAMA Surg. 2013;148:747&#x2013;754.</Citation></Reference><Reference><Citation>Toes-Zoutendijk E, Kooyker AI, Elferink MA, et al. LECO working group. Stage distribution of screen-detected colorectal cancers in the Netherlands. Gut. 2018;67:1745&#x2013;1746.</Citation></Reference><Reference><Citation>Mengual-Ballester M, Pellicer-Franco E, Valero-Navarro G, Soria-Aledo V, Garc&#xed;a-Mar&#xed;n JA, Aguayo-Albasini JL. Increased survival and decreased recurrence in colorectal cancer patients diagnosed in a screening programme. Cancer Epidemiol. 2016;43:70&#x2013;75.</Citation></Reference><Reference><Citation>Stats Canada C. Population estimates, quarterly. Population estimates, quarterly. Published May 30, 2021. Accessed May 30, 2021. https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1710000901 .</Citation></Reference><Reference><Citation>Toward Optimized Practice (TOP) Working Group for Colorectal Cancer Screening. Colorectal cancer screening: clinical practice guideline. Toward Optimized Practice Published November 2013. Accessed December 13, 2020. http://www.topalbertadoctors.org .</Citation></Reference><Reference><Citation>Wong C, Yang H, Zupancic M. Alberta Colorectal Cancer Screening Program. Published January 2014. Accessed August 14, 2021. https://screeningforlife.ca/wp-content/uploads/2019/12/ACRCSP-Program-and-Practice-Standards-and-Guidelines-Jan-2014.pdf .</Citation></Reference><Reference><Citation>Fitzpatrick-Lewis D, Usman A, Warren R, et al. Screening for colorectal cancer. Published August 2014. Accessed November 17, 2020. https://canadiantaskforce.ca/wp-content/uploads/2016/03/crc-screeningfinal031216.pdf .</Citation></Reference><Reference><Citation>Davidson KW, Pennells L, Di Angelantonio E. Depression and incident cardiovascular disease-reply. JAMA. 2021;325:1680.</Citation></Reference><Reference><Citation>nhs.uk. Bowel scope screening. Published February 13, 2018. Accessed November 20, 2020. https://www.nhs.uk/conditions/bowel-cancer-screening/bowel-scope-screening/ .</Citation></Reference><Reference><Citation>Government of Canada SC. Life expectancy and other elements of the life table, Canada, all provinces except Prince Edward Island. Published June 28, 2018. Accessed November 17, 2020. https://www150.statcan.gc.ca/t1/tbl1/en/tv.action?pid=1310011401 .</Citation></Reference><Reference><Citation>Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373&#x2013;383.</Citation></Reference><Reference><Citation>Canadian Task Force on Preventive Health Care. Recommendations on screening for colorectal cancer in primary care. CMAJ. 2016;188:340&#x2013;348.</Citation></Reference><Reference><Citation>U.S. Preventive Services Task Force. Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med. 2008;149:627&#x2013;637.</Citation></Reference><Reference><Citation>Walter LC, Lindquist K, Nugent S, et al. Impact of age and comorbidity on colorectal cancer screening among older veterans. Ann Intern Med. 2009;150:465&#x2013;473.</Citation></Reference><Reference><Citation>Heflin MT, Oddone EZ, Pieper CF, Burchett BM, Cohen HJ. The effect of comorbid illness on receipt of cancer screening by older people. J Am Geriatr Soc. 2002;50:1651&#x2013;1658.</Citation></Reference><Reference><Citation>Schonberg MA, Breslau ES, Hamel MB, Bellizzi KM, McCarthy EP. Colon cancer screening in U.S. adults aged 65 and older according to life expectancy and age. J Am Geriatr Soc. 2015;63:750&#x2013;756.</Citation></Reference><Reference><Citation>Kistler CE, Kirby KA, Lee D, Casadei MA, Walter LC. Long-term outcomes following positive fecal occult blood test results in older adults: benefits and burdens. Arch Intern Med. 2011;171:1344&#x2013;1351.</Citation></Reference><Reference><Citation>Saraste D, Martling A, Nilsson PJ, Blom J, T&#xf6;rnberg S, Janson M. Screening vs. non-screening detected colorectal cancer: differences in pre-therapeutic work up and treatment. J Med Screen. 2017;24:69&#x2013;74.</Citation></Reference><Reference><Citation>Mothes H, Bauschke A, Schuele S, Eigendorff E, Altendorf-Hofmann A, Settmacher U. Surgery for colorectal cancer in elderly patients: how can we improve outcome? J Cancer Res Clin Oncol. 2017;143:1879&#x2013;1889.</Citation></Reference><Reference><Citation>Ming-Gao G, Jian-Zhong D, Yu W, You-Ben F, Xin-Yu H. Colorectal cancer treatment in octogenarians: elective or emergency surgery? World J Surg Oncol. 2014;12:386.</Citation></Reference><Reference><Citation>Hardcastle JD, Chamberlain JO, Robinson MH, et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet. 1996;348:1472&#x2013;1477.</Citation></Reference><Reference><Citation>Lin OS, Kozarek RA, Schembre DB, et al. Screening colonoscopy in very elderly patients: prevalence of neoplasia and estimated impact on life expectancy. JAMA. 2006;295:2357&#x2013;2365.</Citation></Reference><Reference><Citation>Kahi CJ, Azzouz F, Juliar BE, Imperiale TF. Survival of elderly persons undergoing colonoscopy: implications for colorectal cancer screening and surveillance. Gastrointest Endosc. 2007;66:544&#x2013;550.</Citation></Reference><Reference><Citation>Ko CW, Sonnenberg A. Comparing risks and benefits of colorectal cancer screening in elderly patients. Gastroenterology. 2005;129:1163&#x2013;1170.</Citation></Reference><Reference><Citation>Singhal S, Changela K, Basi P, et al. Prescreening with FOBT improves yield and is cost-effective in colorectal screening in the elderly. ISRN Gastroenterol. 2014;2014:179291.</Citation></Reference><Reference><Citation>Isohata N, Shimojima R, Utano K, et al. Colonoscopy in patients aged 85 years or older: an observational study. J Anus Rectum Colon. 2018;2:155&#x2013;161.</Citation></Reference><Reference><Citation>van Hees F, Habbema JD, Meester RG, Lansdorp-Vogelaar I, van Ballegooijen M, Zauber AG. Should colorectal cancer screening be considered in elderly persons without previous screening? A cost-effectiveness analysis. Ann Intern Med. 2014;160:750&#x2013;759.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35485833</PMID><DateCompleted><Year>2023</Year><Month>09</Month><Day>12</Day></DateCompleted><DateRevised><Year>2025</Year><Month>05</Month><Day>05</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>66</Volume><Issue>10</Issue><PubDate><Year>2023</Year><Month>Oct</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Neoadjuvant Immune Checkpoint Inhibition Improves Organ Preservation in T4bM0 Colorectal Cancer With Mismatch Repair Deficiency: A Retrospective Observational Study.</ArticleTitle><Pagination><StartPage>e996</StartPage><EndPage>e1005</EndPage><MedlinePgn>e996-e1005</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002466</ELocationID><Abstract><AbstractText Label="BACKGROUND">Colorectal cancer with mismatch repair deficiency is usually less aggressive and associated with a lower risk of distant metastasis. Immune checkpoint inhibition, rather than traditional chemoradiotherapy, has shown great advantages in treating such patients.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to verify the hypothesis that locally very advanced (T4b) colorectal cancer without distant metastases might present with higher probability of mismatch repair deficiency and be more sensitive to neoadjuvant immune checkpoint inhibition.</AbstractText><AbstractText Label="DESIGN">This study was designed as a single-center retrospective observational study.</AbstractText><AbstractText Label="SETTINGS">The study was conducted in a tertiary referral center in China.</AbstractText><AbstractText Label="PATIENTS">The study included patients who were clinically diagnosed with T4bM0 colorectal cancer from 2008 to 2019.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Clinicopathological characteristics, mismatch repair status, and survival outcomes of patients with mismatch repair deficiency were analyzed.</AbstractText><AbstractText Label="RESULTS">A total of 268 patients were included. The incidence of patients with mismatch repair deficiency in the T4bM0 population was 27.6% (75/268), with 84.0% (63/75) in the colon and 16.0% (12/75) in the rectum. For tumors located in the proximal colon, 45.0% (50/111) exhibited mismatch repair deficiency, whereas the incidence of mismatch repair deficiency in sigmoid colon cancer and rectal cancer was only 15.9% (25/157). Neoadjuvant immune checkpoint inhibition significantly reduced the open surgery rate ( p = 0.000) and multivisceral resection rate ( p = 0.025). The pathological complete remission rate in the neoadjuvant immune checkpoint inhibition group was significantly higher than that in neoadjuvant chemoradiotherapy/chemotherapy group (70.0% vs 0%; p = 0.004). No tumor downstaging was observed after neoadjuvant chemotherapy. Neoadjuvant immune checkpoint inhibition provided significantly better disease-free survival ( p = 0.0078) and relatively longer overall survival ( p = 0.15) than other groups.</AbstractText><AbstractText Label="LIMITATIONS">This study is limited by the possible selection bias and small sample size.</AbstractText><AbstractText Label="CONCLUSIONS">Our data depicted the high incidence of mismatch repair deficiency in T4bM0 mismatch repair deficiency and the effectiveness of the neoadjuvant immune checkpoint inhibition group in organ preservation. Precision oncology requires identification of the protein status of mismatch repair at initial diagnosis to make a rational treatment decision for these patients. See Video Abstract at http://links.lww.com/DCR/B952 .</AbstractText><AbstractText Label="LA INHIBICIN DEL PUNTO DE CONTROL INMUNITARIO NEOADYUVANTE MEJORA LA PRESERVACIN DE RGANOS EN EL CNCER COLORRECTAL TBM CON DEFICIENCIA DE REPARACIN DE ERRORES DE COINCIDENCIA UN ESTUDIO OBSERVACIONAL RETROSPECTIVO">ANTECEDENTES:Los pacientes con c&#xe1;ncer colorrectal con deficiencia en la reparaci&#xf3;n de desajustes suelen (dMMR) ser menos agresivos y se asocian con un menor riesgo de met&#xe1;stasis a distancia. La inhibici&#xf3;n del punto de control inmunitario, en lugar de la quimiorradioterapia tradicional, ha mostrado grandes ventajas en el tratamiento de estos pacientes.OBJETIVO:Este estudio tuvo como objetivo verificar nuestra hip&#xf3;tesis de que el CCR localmente muy avanzado (T4b) sin met&#xe1;stasis a distancia podr&#xed;a presentarse con una mayor probabilidad de dMMR y ser m&#xe1;s sensible a la inhibici&#xf3;n del punto de control inmunitario neoadyuvante.DISE&#xd1;O:Este estudio fue dise&#xf1;ado como un estudio observacional retrospectivo de un solo centro.CONFIGURACI&#xd3;N:El estudio se realiz&#xf3; en un centro de referencia terciario en China.PACIENTES:Se incluyeron pacientes con diagn&#xf3;stico cl&#xed;nico de CCR T4bM0 desde 2008 hasta 2019.PRINCIPALES MEDIDAS DE RESULTADO:Se analizaron las caracter&#xed;sticas clinicopatol&#xf3;gicas, el estado de MMR y los resultados de supervivencia de los pacientes con dMMR.RESULTADOS:Se incluyeron un total de 268 pacientes. La incidencia de dMMR en la poblaci&#xf3;n T4bM0 fue del 27,6% (75/268), con un 84,0% (63/75) en colon y un 16,0% (12/75) en recto. Para los tumores ubicados en el colon proximal, el 45,0% (50/111) exhibi&#xf3; dMMR, mientras que la incidencia de dMMR en el c&#xe1;ncer de colon sigmoideo y el c&#xe1;ncer de recto fue solo del 15,9% (25/157). La inhibici&#xf3;n del punto de control inmunitario neoadyuvante redujo significativamente la cirug&#xed;a abierta y la tasa de resecci&#xf3;n multivisceral ( p = 0,000 y p = 0,025, respectivamente). La tasa de PCR en el grupo de inhibici&#xf3;n del punto de control inmunitario neoadyuvante fue significativamente mayor que en el grupo de quimiorradioterapia/quimioterapia neoadyuvante (70,0% frente a 0%, p = 0,004). No se observ&#xf3; reducci&#xf3;n del estadio del tumor despu&#xe9;s de la quimioterapia neoadyuvante. La inhibici&#xf3;n del punto de control inmunitario neoadyuvante proporcion&#xf3; una supervivencia sin enfermedad significativamente mejor ( p = 0,0078) y una supervivencia general relativamente m&#xe1;s larga ( p = 0,15) que otros grupos.LIMITACIONES:Este estudio est&#xe1; limitado por el posible sesgo de selecci&#xf3;n y el peque&#xf1;o tama&#xf1;o de la muestra.CONCLUSIONES:Nuestros datos representan la alta incidencia de dMMR en T4bM0 CRC y la eficacia del grupo de inhibici&#xf3;n del punto de control inmunitario neoadyuvante en la preservaci&#xf3;n de &#xf3;rganos. La oncolog&#xed;a de precisi&#xf3;n requiere la identificaci&#xf3;n del estado de la prote&#xed;na MMR en el diagn&#xf3;stico inicial para tomar una decisi&#xf3;n de tratamiento racional para estos pacientes especiales. Consulte el Video Resumen en http://links.lww.com/DCR/B952 . (Traducci&#xf3;n-Dr. Yesenia Rojas-Khalil ).</AbstractText><CopyrightInformation>Copyright &#xa9; The ASCRS 2022.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Han</LastName><ForeName>Kai</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Jing-Hua</ForeName><Initials>JH</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Liao</LastName><ForeName>Le-En</ForeName><Initials>LE</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jiang</LastName><ForeName>Wu</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sui</LastName><ForeName>Qiao-Qi</ForeName><Initials>QQ</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xiao</LastName><ForeName>Bin-Yi</ForeName><Initials>BY</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Wei-Rong</ForeName><Initials>WR</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hong</LastName><ForeName>Zhi-Gang</ForeName><Initials>ZG</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Yuan</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kong</LastName><ForeName>Ling-Heng</ForeName><Initials>LH</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Li</LastName><ForeName>Dan-Dan</ForeName><Initials>DD</Initials><AffiliationInfo><Affiliation>Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biological Therapy Center, Sun Yat-sen University Cancer Center, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zhang</LastName><ForeName>Xiao-Shi</ForeName><Initials>XS</Initials><AffiliationInfo><Affiliation>Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Biological Therapy Center, Sun Yat-sen University Cancer Center, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Pan</LastName><ForeName>Zhi-Zhong</ForeName><Initials>ZZ</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Steele</LastName><ForeName>Scott R</ForeName><Initials>SR</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Digestive Disease &amp; Surgery Institute, Cleveland Clinic, Cleveland, Ohio.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ding</LastName><ForeName>Pei-Rong</ForeName><Initials>PR</Initials><AffiliationInfo><Affiliation>Department of Colorectal Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Sun Yat-sen University Cancer Center; State Key Laboratory of Oncology in South China; Collaborative Innovation Center for Cancer Medicine, Guangzhou, China.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D064888">Observational Study</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2023</Year><Month>03</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000082082">Immune Checkpoint Inhibitors</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Disease" UI="C536928">Turcot syndrome</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000082082" MajorTopicYN="N">Immune Checkpoint Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009926" MajorTopicYN="N">Organ Preservation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D057285" MajorTopicYN="N">Precision Medicine</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015179" MajorTopicYN="Y">Colorectal Neoplasms</DescriptorName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="Y">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000601" MajorTopicYN="N">surgery</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053843" MajorTopicYN="N">DNA Mismatch Repair</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="medline"><Year>2023</Year><Month>9</Month><Day>12</Day><Hour>6</Hour><Minute>42</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>4</Month><Day>30</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>4</Month><Day>29</Day><Hour>8</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35485833</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002466</ArticleId><ArticleId IdType="pii">00003453-202310000-00011</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Andr&#xe9; T, Boni C, Navarro M, et al. Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. J Clin Oncol. 2009;27:3109&#x2013;3116.</Citation></Reference><Reference><Citation>Croner RS, Merkel S, Papadopoulos T, Schellerer V, Hohenberger W, Goehl J. Multivisceral resection for colon carcinoma. Dis Colon Rectum. 2009;52:1381&#x2013;1386.</Citation></Reference><Reference><Citation>Lehnert T, Methner M, Pollok A, Schaible A, Hinz U, Herfarth C. Multivisceral resection for locally advanced primary colon and rectal cancer: an analysis of prognostic factors in 201 patients. Ann Surg. 2002;235:217&#x2013;225.</Citation></Reference><Reference><Citation>Takano S, Kato J, Yamamoto H, et al. Identification of risk factors for lymph node metastasis of colorectal cancer. Hepatogastroenterology. 2007;54:746&#x2013;750.</Citation></Reference><Reference><Citation>Hasebe T, Morihiro M, Sasaki S, et al. Tumor thickness is a histopathologic predictive parameter of tumor metastasis and prognosis in patients with Dukes stage C ulcerative-type colorectal carcinoma. A two-hospital-based study. Cancer. 2000;89:35&#x2013;45.</Citation></Reference><Reference><Citation>Cunningham D, Allum WH, Stenning SP, et al. Perioperative chemotherapy versus surgery alone for resectable gastroesophageal cancer. N Engl J Med. 2006;355:11&#x2013;20.</Citation></Reference><Reference><Citation>Medical Research Council Oesophageal Cancer Working Group. Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trial. Lancet. 2002;359:1727&#x2013;1733.</Citation></Reference><Reference><Citation>Nelson H, Petrelli N, Carlin A, et al.; National Cancer Institute Expert Panel. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst. 2001;93:583&#x2013;596.</Citation></Reference><Reference><Citation>Sebag-Montefiore D, Stephens RJ, Steele R, et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet. 2009;373:811&#x2013;820.</Citation></Reference><Reference><Citation>Foxtrot Collaborative Group. Feasibility of preoperative chemotherapy for locally advanced, operable colon cancer: the pilot phase of a randomised controlled trial. Lancet Oncol. 2012;13:1152&#x2013;1160.</Citation></Reference><Reference><Citation>Sargent DJ, Marsoni S, Monges G, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28:3219&#x2013;3226.</Citation></Reference><Reference><Citation>Cercek A, Dos Santos Fernandes G, Roxburgh CS, et al. Mismatch repair-deficient rectal cancer and resistance to neoadjuvant chemotherapy. Clin Cancer Res. 2020;26:3271&#x2013;3279.</Citation></Reference><Reference><Citation>Hasan S, Renz P, Wegner RE, et al. Microsatellite instability (MSI) as an independent predictor of pathologic complete response (PCR) in locally advanced rectal cancer: a National Cancer Database (NCDB) analysis. Ann Surg. 2020;271:716&#x2013;723.</Citation></Reference><Reference><Citation>Luchini C, Bibeau F, Ligtenberg MJL, et al. ESMO recommendations on microsatellite instability testing for immunotherapy in cancer, and its relationship with PD-1/PD-L1 expression and tumour mutational burden: a systematic review-based approach. Ann Oncol. 2019;30:1232&#x2013;1243.</Citation></Reference><Reference><Citation>Moreira L, Balaguer F, Lindor N, et al.; EPICOLON Consortium. Identification of Lynch syndrome among patients with colorectal cancer. JAMA. 2012;308:1555&#x2013;1565.</Citation></Reference><Reference><Citation>Ganesh K, Stadler ZK, Cercek A, et al. Immunotherapy in colorectal cancer: rationale, challenges and potential. Nat Rev Gastroenterol Hepatol. 2019;16:361&#x2013;375.</Citation></Reference><Reference><Citation>Chalabi M, Fanchi LF, Dijkstra KK, et al. Neoadjuvant immunotherapy leads to pathological responses in MMR-proficient and MMR-deficient early-stage colon cancers. Nat Med. 2020;26:566&#x2013;576.</Citation></Reference><Reference><Citation>Joost P, Veurink N, Holck S, et al. Heterogenous mismatch-repair status in colorectal cancer. Diagn Pathol. 2014;9:126.</Citation></Reference><Reference><Citation>McCarthy AJ, Capo-Chichi JM, Spence T, et al. Heterogenous loss of mismatch repair (MMR) protein expression: a challenge for immunohistochemical interpretation and microsatellite instability (MSI) evaluation. J Pathol Clin Res. 2019;5:115&#x2013;129.</Citation></Reference><Reference><Citation>Gao P, Song YX, Wang ZN, et al. Is the prediction of prognosis not improved by the seventh edition of the TNM classification for colorectal cancer? Analysis of the Surveillance, Epidemiology, and End Results (SEER) database. BMC Cancer. 2013;13:123.</Citation></Reference><Reference><Citation>Hampel H, Frankel WL, Martin E, et al. Feasibility of screening for Lynch syndrome among patients with colorectal cancer. J Clin Oncol. 2008;26:5783&#x2013;5788.</Citation></Reference><Reference><Citation>Jiang W, Cai MY, Li SY, et al.; Written on behalf of AME Colorectal Cancer Cooperative Group. Universal screening for Lynch syndrome in a large consecutive cohort of Chinese colorectal cancer patients: high prevalence and unique molecular features. Int J Cancer. 2019;144:2161&#x2013;2168.</Citation></Reference><Reference><Citation>Evrard C, Tachon G, Randrian V, Karayan-Tapon L, Tougeron D. Microsatellite Instability: Diagnosis, Heterogeneity, Discordance, and Clinical Impact in Colorectal Cancer. Cancers (Basel). 2019;11:E1567.</Citation></Reference><Reference><Citation>Dighe S, Blake H, Koh MD, et al. Accuracy of multidetector computed tomography in identifying poor prognostic factors in colonic cancer. Br J Surg. 2010;97:1407&#x2013;1415.</Citation></Reference><Reference><Citation>Halefoglu AM, Yildirim S, Avlanmis O, Sakiz D, Baykan A. Endorectal ultrasonography versus phased-array magnetic resonance imaging for preoperative staging of rectal cancer. World J Gastroenterol. 2008;14:3504&#x2013;3510.</Citation></Reference><Reference><Citation>Overman MJ, McDermott R, Leach JL, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:1182&#x2013;1191.</Citation></Reference><Reference><Citation>Overman MJ, Lonardi S, Wong KYM, et al. Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer. J Clin Oncol. 2018;36:773&#x2013;779.</Citation></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34657078</PMID><DateCompleted><Year>2021</Year><Month>12</Month><Day>30</Day></DateCompleted><DateRevised><Year>2023</Year><Month>08</Month><Day>14</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>12</Issue><PubDate><Year>2021</Year><Month>Dec</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>The Impact of Chronic Kidney Disease in Patients With Locally Advanced Rectal Cancer Treated With Neoadjuvant Chemoradiation.</ArticleTitle><Pagination><StartPage>1471</StartPage><EndPage>1478</EndPage><MedlinePgn>1471-1478</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002116</ELocationID><Abstract><AbstractText Label="BACKGROUND">Patients with chronic kidney disease are commonly excluded from clinical trials. The impact of chronic kidney disease on outcomes in patients with locally advanced rectal cancer has not been previously studied.</AbstractText><AbstractText Label="OBJECTIVE">This study aimed to investigate the impact of chronic kidney disease on outcomes in patients with locally advanced rectal cancer.</AbstractText><AbstractText Label="DESIGN">This is a multi-institutional, retrospective cohort study.</AbstractText><AbstractText Label="SETTINGS">This study was conducted at academic and community cancer centers participating in the Canadian Health Outcomes Research Database Consortium Rectal Cancer Database.</AbstractText><AbstractText Label="PATIENTS">Consecutive patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation before curative-intent surgery from 2005 to 2013 were selected.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Disease-free survival, overall survival, pathologic complete response, and neoadjuvant chemotherapy/radiotherapy completion rate were the primary outcomes measured.</AbstractText><AbstractText Label="RESULTS">A total of 1254 patients were included. Median age was 62, and 29%/69% had clinical stage II and III disease. Median estimated creatinine clearance was 93&#x2009;mL/min, with 11% &lt;60&#x2009;mL/min (n = 136). There was no significant difference in the completion rate of neoadjuvant chemotherapy (82% vs 85%, p = 0.36) or radiotherapy (93% vs 95%, p = 0.45) between patients with and without chronic kidney disease. Patients with chronic kidney disease were less likely to receive adjuvant chemotherapy (63% vs 77%, p &lt; 0.01). On multivariate analysis, patients with chronic kidney disease had decreased disease-free survival (HR, 1.37; 95% CI, 1.03-1.82; p = 0.03) but not overall survival (HR, 1.23; 95% CI, 0.88-1.75; p = 0.23) or pathologic complete response (OR, 0.83; 95% CI, 0.50-1.39; p = 0.71).</AbstractText><AbstractText Label="LIMITATIONS">This study was limited by its retrospective design and by limited events for overall survival analysis.</AbstractText><AbstractText Label="CONCLUSIONS">In patients with locally advanced rectal cancer undergoing neoadjuvant chemoradiation, baseline chronic kidney disease was associated with less use of adjuvant chemotherapy and decreased disease-free survival. Chronic kidney disease was not independently associated with neoadjuvant chemotherapy/radiotherapy completion rate, pathologic complete response, or overall survival. These data suggest that patients with locally advanced rectal cancer with chronic kidney disease may have distinct outcomes and, accordingly, the results of landmark clinical trials may not be generalizable to this population. See Video Abstract at http://links.lww.com/DCR/B694.</AbstractText><AbstractText Label="LA REPERCUSIN DE LA ENFERMEDAD RENAL CRNICA EN PACIENTES CON CNCER DE RECTO LOCALMENTE AVANZADO TRATADOS CON QUIMIORRADIOTERAPIA NEOADYUVANTE">ANTECEDENTES:Los pacientes con enfermedad renal cr&#xf3;nica generalmente se excluyen de los ensayos cl&#xed;nicos. La repercusi&#xf3;n de la enfermedad renal cr&#xf3;nica en el desenlace en pacientes con c&#xe1;ncer de recto localmente avanzado no se ha estudiado previamente.OBJETIVO:Investigar la repercusi&#xf3;n de la enfermedad renal cr&#xf3;nica en los desenlaces en pacientes con c&#xe1;ncer de recto localmente avanzado.DISE&#xd1;O:Estudio de cohorte retrospectivo multiinstitucional.ESCENARIO:Centros oncol&#xf3;gicos acad&#xe9;micos y comunitarios que participan en la base de datos de c&#xe1;ncer rectal del consorcio CHORD.PACIENTES:Pacientes consecutivos con c&#xe1;ncer de recto localmente avanzado, tratados con quimiorradioterapia neoadyuvante, previa a la cirug&#xed;a con intenci&#xf3;n curativa del 2005 al 2013.PRINCIPALES VARIABLES EVALUADAS:Sobrevida libre de enfermedad, sobrevida global, respuesta patol&#xf3;gica completa, tasa de conclusi&#xf3;n de quimioterapia / radioterapia neoadyuvante.RESULTADOS:Se incluyeron 1254 pacientes. El promedio de edad fue de 62, y el 29% / 69% ten&#xed;an enfermedad en estadio cl&#xed;nico II y III, respectivamente. El promedio de la depuraci&#xf3;n de creatinina estimada fue de 93 mililitros / minuto, con un 11% &lt;60 mililitros / minuto (n = 136). No hubo diferencias significativas en la tasa de conclusi&#xf3;n de la quimioterapia neoadyuvante (82% vs 85%, p = 0,36) o radioterapia (93% vs 95%, p = 0,45) entre pacientes con y sin enfermedad renal cr&#xf3;nica. Los pacientes con enfermedad renal cr&#xf3;nica ten&#xed;an menos probabilidades de recibir quimioterapia adyuvante (63% contra el 77%, p &lt;0,01). En el an&#xe1;lisis multivariado, los pacientes con enfermedad renal cr&#xf3;nica ten&#xed;an una sobrevida libre de enfermedad menor (HR 1,37, IC 95% 1,03-1,82, p = 0,03) pero no en la sobrevida global (HR 1,23, IC 95% 0,88-1,75, p = 0,23) o respuesta patol&#xf3;gica completa (OR 0,83, IC 95% 0,50-1,39, p = 0,71).LIMITACIONES:Dise&#xf1;o retrospectivo y acontecimientos limitados para el an&#xe1;lisis de sobrevida global.CONCLUSIONES:En pacientes con c&#xe1;ncer de recto localmente avanzado tratados con quimiorradioterapia neoadyuvante, la enfermedad renal cr&#xf3;nica de base se asoci&#xf3; con un menor uso de quimioterapia adyuvante y una menor sobrevida libre de enfermedad. La enfermedad renal cr&#xf3;nica no se asoci&#xf3; de forma independiente con la tasa de conclusi&#xf3;n de la quimioterapia / radioterapia neoadyuvante, la respuesta patol&#xf3;gica completa o la sobrevida global. Estos datos sugieren que los pacientes con c&#xe1;ncer de recto localmente avanzado con enfermedad renal cr&#xf3;nica pueden tener resultados distintos y, en consecuencia, los resultados de los ensayos cl&#xed;nicos de referencia pueden no ser generalizables a esta poblaci&#xf3;n. Consulte Video Resumen en http://links.lww.com/DCR/B694.</AbstractText><CopyrightInformation>Copyright &#xa9; 2021 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Society of Colon and Rectal Surgeons.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Dudani</LastName><ForeName>Shaan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>The Ottawa Hospital Cancer Centre/University of Ottawa, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marginean</LastName><ForeName>Horia</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>The Ottawa Hospital Cancer Centre/University of Ottawa, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gotfrit</LastName><ForeName>Joanna</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>The Ottawa Hospital Cancer Centre/University of Ottawa, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Tang</LastName><ForeName>Patricia A</ForeName><Initials>PA</Initials><AffiliationInfo><Affiliation>Alberta Health Services/University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Monzon</LastName><ForeName>Jose Gerard</ForeName><Initials>JG</Initials><AffiliationInfo><Affiliation>Alberta Health Services/University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dennis</LastName><ForeName>Kristopher</ForeName><Initials>K</Initials><AffiliationInfo><Affiliation>The Ottawa Hospital Cancer Centre/University of Ottawa, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kennecke</LastName><ForeName>Hagen F</ForeName><Initials>HF</Initials><AffiliationInfo><Affiliation>British Columbia Cancer Agency, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Powell</LastName><ForeName>Erin D</ForeName><Initials>ED</Initials><AffiliationInfo><Affiliation>Dr. H Bliss Murphy Cancer Centre, St. John's, Newfoundland, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Babak</LastName><ForeName>Sam</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Alberta Health Services/University of Calgary, Calgary, Alberta, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cheung</LastName><ForeName>Winson Y</ForeName><Initials>WY</Initials><AffiliationInfo><Affiliation>British Columbia Cancer Agency, Vancouver, British Columbia, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Vickers</LastName><ForeName>Michael M</ForeName><Initials>MM</Initials><AffiliationInfo><Affiliation>The Ottawa Hospital Cancer Centre/University of Ottawa, Ottawa, Ontario, Canada.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D016448">Multicenter Study</PublicationType><PublicationType UI="D057405">Webcast</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="CommentIn"><RefSource>Dis Colon Rectum. 2021 Dec 1;64(12):1441-1443. doi: 10.1097/DCR.0000000000002254.</RefSource><PMID Version="1">34561345</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D002170" MajorTopicYN="N" Type="Geographic">Canada</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059248" MajorTopicYN="N">Chemoradiotherapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018572" MajorTopicYN="N">Disease-Free Survival</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008657" MajorTopicYN="N">Metabolic Clearance Rate</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D020360" MajorTopicYN="N">Neoadjuvant Therapy</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D009367" MajorTopicYN="N">Neoplasm Staging</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017063" MajorTopicYN="N">Outcome Assessment, Health Care</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012004" MajorTopicYN="N">Rectal Neoplasms</DescriptorName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName><QualifierName UI="Q000473" MajorTopicYN="N">pathology</QualifierName><QualifierName UI="Q000532" MajorTopicYN="Y">radiotherapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D051436" MajorTopicYN="N">Renal Insufficiency, Chronic</DescriptorName><QualifierName UI="Q000097" MajorTopicYN="N">blood</QualifierName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>10</Month><Day>18</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>12</Month><Day>31</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>10</Month><Day>17</Day><Hour>20</Hour><Minute>54</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2021</Year><Month>11</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34657078</ArticleId><ArticleId IdType="pmc">PMC8568328</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002116</ArticleId><ArticleId IdType="pii">00003453-202112000-00008</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Levey AS, Coresh J. Chronic kidney disease. Lancet. 2012;379:165&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">21840587</ArticleId></ArticleIdList></Reference><Reference><Citation>Stevens PE, Levin A; Kidney Disease: Improving Global Outcomes Chronic Kidney Disease Guideline Development Work Group Members. Evaluation and management of chronic kidney disease: synopsis of the kidney disease: improving global outcomes 2012 clinical practice guideline. Ann Intern Med. 2013;158:825&#x2013;830.</Citation><ArticleIdList><ArticleId IdType="pubmed">23732715</ArticleId></ArticleIdList></Reference><Reference><Citation>Iff S, Craig JC, Turner R, et al. . Reduced estimated GFR and cancer mortality. Am J Kidney Dis. 2014;63:23&#x2013;30.</Citation><ArticleIdList><ArticleId IdType="pubmed">23993153</ArticleId></ArticleIdList></Reference><Reference><Citation>Na SY, Sung JY, Chang JH, et al. . Chronic kidney disease in cancer patients: an independent predictor of cancer-specific mortality. Am J Nephrol. 2011;33:121&#x2013;130.</Citation><ArticleIdList><ArticleId IdType="pubmed">21242672</ArticleId></ArticleIdList></Reference><Reference><Citation>K&#xf6;nigsbr&#xfc;gge O, L&#xf6;tsch F, Zielinski C, Pabinger I, Ay C. Chronic kidney disease in patients with cancer and its association with occurrence of venous thromboembolism and mortality. Thromb Res. 2014;134:44&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pubmed">24792954</ArticleId></ArticleIdList></Reference><Reference><Citation>Launay-Vacher V. Epidemiology of chronic kidney disease in cancer patients: lessons from the IRMA study group. Semin Nephrol. 2010;30:548&#x2013;556.</Citation><ArticleIdList><ArticleId IdType="pubmed">21146120</ArticleId></ArticleIdList></Reference><Reference><Citation>Lichtman SM, Harvey RD, Damiette Smit MA, et al. . Modernizing Clinical Trial Eligibility Criteria: Recommendations of the American Society of Clinical Oncology-Friends of Cancer Research Organ Dysfunction, Prior or Concurrent Malignancy, and Comorbidities Working Group. J Clin Oncol. 2017;35:3753&#x2013;3759.</Citation><ArticleIdList><ArticleId IdType="pubmed">28968172</ArticleId></ArticleIdList></Reference><Reference><Citation>Stengel B. Chronic kidney disease and cancer: a troubling connection. J Nephrol. 2010;23:253&#x2013;262.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4823382</ArticleId><ArticleId IdType="pubmed">20349418</ArticleId></ArticleIdList></Reference><Reference><Citation>Izzedine H, Perazella MA. Onco-nephrology: an appraisal of the cancer and chronic kidney disease links. Nephrol Dial Transplant. 2015;30:1979&#x2013;1988.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4832985</ArticleId><ArticleId IdType="pubmed">25648910</ArticleId></ArticleIdList></Reference><Reference><Citation>Sauer R, Fietkau R, Wittekind C, et al. ; German Rectal Cancer Group. Adjuvant vs. neoadjuvant radiochemotherapy for locally advanced rectal cancer: the German trial CAO/ARO/AIO-94. Colorectal Dis. 2003;5:406&#x2013;415.</Citation><ArticleIdList><ArticleId IdType="pubmed">12925071</ArticleId></ArticleIdList></Reference><Reference><Citation>Dudani S, Marginean H, Tang PA, et al. . Neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios as predictive and prognostic markers in patients with locally advanced rectal cancer treated with neoadjuvant chemoradiation. BMC Cancer. 2019;19:664.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6612202</ArticleId><ArticleId IdType="pubmed">31277604</ArticleId></ArticleIdList></Reference><Reference><Citation>Edge SB, Compton CC. The American Joint Committee on Cancer: the 7th edition of the AJCC cancer staging manual and the future of TNM. Ann Surg Oncol. 2010;17:1471&#x2013;1474.</Citation><ArticleIdList><ArticleId IdType="pubmed">20180029</ArticleId></ArticleIdList></Reference><Reference><Citation>Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31&#x2013;41.</Citation><ArticleIdList><ArticleId IdType="pubmed">1244564</ArticleId></ArticleIdList></Reference><Reference><Citation>Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515&#x2013;526.</Citation></Reference><Reference><Citation>Sauer R, Becker H, Hohenberger W, et al. ; German Rectal Cancer Study Group. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med. 2004;351:1731&#x2013;1740.</Citation><ArticleIdList><ArticleId IdType="pubmed">15496622</ArticleId></ArticleIdList></Reference><Reference><Citation>Allegra CJ, Yothers G, O&#x2019;Connell MJ, et al. . Neoadjuvant 5-FU or capecitabine plus radiation with or without oxaliplatin in rectal cancer patients: a phase III randomized clinical trial. J Natl Cancer Inst. 2015;107:djv248.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4849360</ArticleId><ArticleId IdType="pubmed">26374429</ArticleId></ArticleIdList></Reference><Reference><Citation>Hong TS, Ryan DP. Adjuvant chemotherapy for locally advanced rectal cancer: is it a given? J Clin Oncol. 2015;33:1878&#x2013;1880.</Citation><ArticleIdList><ArticleId IdType="pubmed">25940719</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosset JF, Calais G, Mineur L, et al. ; EORTC Radiation Oncology Group. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol. 2014;15:184&#x2013;190.</Citation><ArticleIdList><ArticleId IdType="pubmed">24440473</ArticleId></ArticleIdList></Reference><Reference><Citation>Janowitz T, Williams EH, Marshall A, et al. . New model for estimating glomerular filtration rate in patients with cancer. J Clin Oncol. 2017;35:2798&#x2013;2805.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5562175</ArticleId><ArticleId IdType="pubmed">28686534</ArticleId></ArticleIdList></Reference><Reference><Citation>Pal SK, Ruel N, Villegas S, et al. . CKD-EPI and Cockcroft-Gault equations identify similar candidates for neoadjuvant chemotherapy in muscle-invasive bladder cancer. PLoS One. 2014;9:e94471.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3983198</ArticleId><ArticleId IdType="pubmed">24722472</ArticleId></ArticleIdList></Reference><Reference><Citation>Grillo JA, Abraham S, Khandelwal A, Liu Q, Booth B, Rahman NA. A comparison of the Cockroft-Gault (CG) and the modification of diet in renal disease (MDRD) equations for estimating renal function and guiding dose adjustment of oncology-related drugs. J Clin Oncol. 2010;28:2601&#x2013;2601.</Citation></Reference><Reference><Citation>Sargent DJ, Wieand HS, Haller DG, et al. . Disease-free survival versus overall survival as a primary end point for adjuvant colon cancer studies: individual patient data from 20,898 patients on 18 randomized trials. J Clin Oncol. 2005;23:8664&#x2013;8670.</Citation><ArticleIdList><ArticleId IdType="pubmed">16260700</ArticleId></ArticleIdList></Reference><Reference><Citation>Bosset JF, Collette L, Calais G, et al. ; EORTC Radiotherapy Group Trial 22921. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med. 2006;355:1114&#x2013;1123.</Citation><ArticleIdList><ArticleId IdType="pubmed">16971718</ArticleId></ArticleIdList></Reference><Reference><Citation>Azria D, Doyen J, Jarlier M, et al. . Late toxicities and clinical outcome at 5 years of the ACCORD 12/0405-PRODIGE 02 trial comparing two neoadjuvant chemoradiotherapy regimens for intermediate-risk rectal cancer. Ann Oncol. 2017;28: 2436&#x2013;2442.</Citation><ArticleIdList><ArticleId IdType="pubmed">28961836</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle><PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Manual"><PMID Version="1">34086000</PMID><DateCompleted><Year>2021</Year><Month>10</Month><Day>14</Day></DateCompleted><DateRevised><Year>2025</Year><Month>08</Month><Day>07</Day></DateRevised><Article PubModel="Print"><Journal><ISSN IssnType="Electronic">1530-0358</ISSN><JournalIssue CitedMedium="Internet"><Volume>64</Volume><Issue>7</Issue><PubDate><Year>2021</Year><Month>Jul</Month><Day>01</Day></PubDate></JournalIssue><Title>Diseases of the colon and rectum</Title><ISOAbbreviation>Dis Colon Rectum</ISOAbbreviation></Journal><ArticleTitle>Prevalence of High-Grade Anal Dysplasia and Anal Cancer in Veterans Living With HIV and CD4/CD8 Ratio as a Marker For Increased Risk: A Regional Retrospective Cohort Study.</ArticleTitle><Pagination><StartPage>805</StartPage><EndPage>811</EndPage><MedlinePgn>805-811</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1097/DCR.0000000000002009</ELocationID><Abstract><AbstractText Label="BACKGROUND">The Department of Veterans Affairs cares for the largest population of patients with HIV of any healthcare system in the United States. Screening for anal dysplasia/cancer is recommended for all veterans with HIV. Exams are invasive, burdensome, and resource intensive. We currently lack markers of disease to tailor screening.</AbstractText><AbstractText Label="OBJECTIVE">The purpose of this study was to establish the prevalence of advanced anal disease (high-grade dysplasia and anal cancer) and to determine whether CD4/CD8 ratio correlates with risk.</AbstractText><AbstractText Label="DESIGN">This was a retrospective regional cohort study of veterans with HIV.</AbstractText><AbstractText Label="SETTINGS">The study was conducted at eight medical centers between 2001 and 2019.</AbstractText><AbstractText Label="PATIENTS">Patients with advanced disease were compared with patients with nonadvanced anal pathology.</AbstractText><AbstractText Label="MAIN OUTCOME MEASURES">Logistic regression modeling was used to estimate adjusted odds of disease as a function of CD4/CD8. Lowest (nadir) CD4/CD8 and nearest CD4/CD8 ratio in each cohort were evaluated.</AbstractText><AbstractText Label="RESULTS">A total of 2267 veterans were included. Fifteen percent had anal pathology (112 with advanced disease (37 cancer and 75 high-grade), 222 with nonadvanced disease). Nadir and nearest ratio were lower in patients with advanced disease versus nonadvanced (0.24 vs 0.45 (p &lt; 0.001) and 0.50 vs 0.88 (p &lt; 0.001)). In adjusted models, a 1-unit increase in nadir or nearest ratio conferred decreased risk of advanced disease (OR = 0.19 (95% CI, 0.07-0.53); p &lt; 0.001; OR = 0.22 (95% CI, 0.12-0.43); p &lt; 0.001). Using a minimum sensitivity analysis, a cutoff nadir ratio of 0.42 or nearest ratio of 0.76 could be used to risk stratify.</AbstractText><AbstractText Label="LIMITATIONS">This was a retrospective analysis with a low screening rate.</AbstractText><AbstractText Label="CONCLUSIONS">In a regional cohort of veterans with HIV, 15% were formally assessed for anal dysplasia. Advanced anal disease was present in 33% of those screened, 5% of the HIV-positive population. A strong predictor of advanced disease in this cohort is the CD4/CD8 ratio, which is a promising marker to stratify screening practices. Risk stratification using CD4/CD8 has the potential to decrease burdensome invasive examinations for low-risk patients and to intensify examinations for those at high risk. See Video Abstract at http://links.lww.com/DCR/B528.</AbstractText><AbstractText Label="PREVALENCIA DE DISPLASIA ANAL DE ALTO GRADO Y CNCER ANAL EN VETERANOS QUE VIVEN CON EL VIH Y LA RELACIN CD / CD COMO MARCADOR DE MAYOR RIESGO UN ESTUDIO DE COHORTE REGIONAL RETROSPECTIVE">ANTECEDENTES:El Departamento de Asuntos de Veteranos atiende a la poblaci&#xf3;n m&#xe1;s grande de pacientes con el virus de inmunodeficiencia humana (VIH) de cualquier sistema de salud en los Estados Unidos. Se recomienda la detecci&#xf3;n de displasia / c&#xe1;ncer anal para todos los veteranos con VIH. Los ex&#xe1;menes son invasivos, onerosos y requieren muchos recursos. Actualmente carecemos de marcadores de enfermedad para adaptar la detecci&#xf3;n.OBJETIVO:Establecer la prevalencia de enfermedad anal avanzada (displasia de alto grado y c&#xe1;ncer anal) y determinar si la relaci&#xf3;n CD4 / CD8 se correlaciona con el riesgo.DISE&#xd1;O:Estudio de cohorte regional retrospectivo de veteranos con VIH.AJUSTE:Ocho centros m&#xe9;dicos entre 2001-2019.PACIENTES:Se compar&#xf3; a pacientes con enfermedad avanzada con pacientes con patolog&#xed;a anal no avanzada.PRINCIPALES MEDIDAS DE RESULTADO:Se utiliz&#xf3; un modelo de regresi&#xf3;n log&#xed;stica para estimar las probabilidades ajustadas de enfermedad en funci&#xf3;n de CD4 / CD8. Se evalu&#xf3; la relaci&#xf3;n CD4 / CD8 m&#xe1;s baja (nadir) y la relaci&#xf3;n CD4 / CD8 m&#xe1;s cercana en cada cohorte.RESULTADOS:Se incluyeron un total de 2267 veteranos. El 15% ten&#xed;a patolog&#xed;a anal (112 enfermedad avanzada (37 c&#xe1;ncer, 75 de alto grado), 222 enfermedad no avanzada). El nadir y el cociente m&#xe1;s cercano fueron menores en los pacientes con enfermedad avanzada frente a los no avanzados (0,24 frente a 0,45 (p &lt;0,001) y 0,50 frente a 0,88 (p &lt;0,001)), respectivamente. En modelos ajustados, el aumento de una unidad en el nadir o el cociente m&#xe1;s cercano confiri&#xf3; una disminuci&#xf3;n del riesgo de enfermedad avanzada (OR 0,19 (IC del 95%: 0,07, 0,53, p &lt;0,001)) y (OR 0,22 (IC del 95%: 0,12, 0,43, p &lt;0,001))), respectivamente. Utilizando un an&#xe1;lisis de sensibilidad m&#xed;nima, se podr&#xed;a utilizar un cociente del nadir de corte de 0,42 o el cociente m&#xe1;s cercano de 0,76 para estratificar el riesgo.LIMITACIONES:An&#xe1;lisis retrospectivo con una tasa de detecci&#xf3;n baja.CONCLUSIONES:En una cohorte regional de veteranos con VIH, el 15% fueron evaluados formalmente por displasia anal. La enfermedad anal avanzada estuvo presente en el 33% de los examinados, el 5% de la poblaci&#xf3;n VIH +. Un fuerte predictor de enfermedad avanzada en esta cohorte es la relaci&#xf3;n CD4 / CD8, que es un marcador prometedor para estratificar las pr&#xe1;cticas de detecci&#xf3;n. La estratificaci&#xf3;n del riesgo usando CD4 / CD8 tiene el potencial de disminuir los ex&#xe1;menes invasivos onerosos para los pacientes de bajo riesgo e intensificar los ex&#xe1;menes para los de alto riesgo. Consulte Video Resumen en http://links.lww.com/DCR/B528.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Sanger</LastName><ForeName>Cristina B</ForeName><Initials>CB</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>William S. Middleton Memorial Veteran's Hospital, Madison, Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Xu</LastName><ForeName>Yiwei</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Carchman</LastName><ForeName>Evie</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lawson</LastName><ForeName>Elise H</ForeName><Initials>EH</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heise</LastName><ForeName>Charles P</ForeName><Initials>CP</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Striker</LastName><ForeName>Rob</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>William S. Middleton Memorial Veteran's Hospital, Madison, Wisconsin.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Medicine, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Voils</LastName><ForeName>Corrine I</ForeName><Initials>CI</Initials><AffiliationInfo><Affiliation>Department of Surgery, University of Wisconsin School of Medicine and Public Health, Madison, Wisconsin.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>William S. Middleton Memorial Veteran's Hospital, Madison, Wisconsin.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>P30 CA014520</GrantID><Acronym>CA</Acronym><Agency>NCI NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D059040">Video-Audio Media</PublicationType></PublicationTypeList></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Dis Colon Rectum</MedlineTA><NlmUniqueID>0372764</NlmUniqueID><ISSNLinking>0012-3706</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D001004" MajorTopicYN="N">Anus Diseases</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001005" MajorTopicYN="N">Anus Neoplasms</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015496" MajorTopicYN="N">CD4-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018414" MajorTopicYN="N">CD8-Positive T-Lymphocytes</DescriptorName><QualifierName UI="Q000166" MajorTopicYN="N">cytology</QualifierName><QualifierName UI="Q000473" MajorTopicYN="Y">pathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006678" MajorTopicYN="N">HIV</DescriptorName><QualifierName UI="Q000302" MajorTopicYN="N">isolation &amp; purification</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015658" MajorTopicYN="N">HIV Infections</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016015" MajorTopicYN="N">Logistic Models</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008403" MajorTopicYN="N">Mass Screening</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D060787" MajorTopicYN="N">Neoplasm Grading</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015995" MajorTopicYN="N">Prevalence</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012189" MajorTopicYN="N">Retrospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018570" MajorTopicYN="N">Risk Assessment</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D014481" MajorTopicYN="N" Type="Geographic">United States</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName><QualifierName UI="Q000208" MajorTopicYN="N">ethnology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D014728" MajorTopicYN="N">Veterans</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading></MeshHeadingList><OtherAbstract Type="Publisher" Language="spa"><AbstractText Label="ANTECEDENTES:">El Departamento de Asuntos de Veteranos atiende a la poblaci&#xf3;n m&#xe1;s grande de pacientes con el virus de inmunodeficiencia humana (VIH) de cualquier sistema de salud en los Estados Unidos. Se recomienda la detecci&#xf3;n de displasia / c&#xe1;ncer anal para todos los veteranos con VIH. Los ex&#xe1;menes son invasivos, onerosos y requieren muchos recursos. Actualmente carecemos de marcadores de enfermedad para adaptar la detecci&#xf3;n.</AbstractText><AbstractText Label="OBJETIVO:">Establecer la prevalencia de enfermedad anal avanzada (displasia de alto grado y c&#xe1;ncer anal) y determinar si la relaci&#xf3;n CD4 / CD8 se correlaciona con el riesgo.</AbstractText><AbstractText Label="DISE&#xd1;O:">Estudio de cohorte regional retrospectivo de veteranos con VIH.</AbstractText><AbstractText Label="AJUSTE:">Ocho centros m&#xe9;dicos entre 2001&#x2013;2019.</AbstractText><AbstractText Label="PACIENTES:">Se compar&#xf3; a pacientes con enfermedad avanzada con pacientes con patolog&#xed;a anal no avanzada.</AbstractText><AbstractText Label="PRINCIPALES MEDIDAS DE RESULTADO:">Se utiliz&#xf3; un modelo de regresi&#xf3;n log&#xed;stica para estimar las probabilidades ajustadas de enfermedad en funci&#xf3;n de CD4 / CD8. Se evalu&#xf3; la relaci&#xf3;n CD4 / CD8 m&#xe1;s baja (nadir) y la relaci&#xf3;n CD4 / CD8 m&#xe1;s cercana en cada cohorte.</AbstractText><AbstractText Label="RESULTADOS:">Se incluyeron un total de 2267 veteranos. El 15% ten&#xed;a patolog&#xed;a anal (112 enfermedad avanzada (37 c&#xe1;ncer, 75 de alto grado), 222 enfermedad no avanzada). El nadir y el cociente m&#xe1;s cercano fueron menores en los pacientes con enfermedad avanzada frente a los no avanzados (0,24 frente a 0,45 (p &lt;0,001) y 0,50 frente a 0,88 (p &lt;0,001)), respectivamente. En modelos ajustados, el aumento de una unidad en el nadir o el cociente m&#xe1;s cercano confiri&#xf3; una disminuci&#xf3;n del riesgo de enfermedad avanzada (OR 0,19 (IC del 95%: 0,07, 0,53, p &lt;0,001)) y (OR 0,22 (IC del 95%: 0,12, 0,43, p &lt;0,001) )), respectivamente. Utilizando un an&#xe1;lisis de sensibilidad m&#xed;nima, se podr&#xed;a utilizar un cociente del nadir de corte de 0,42 o el cociente m&#xe1;s cercano de 0,76 para estratificar el riesgo.</AbstractText><AbstractText Label="LIMITACIONES:">An&#xe1;lisis retrospectivo con una tasa de detecci&#xf3;n baja.</AbstractText><AbstractText Label="CONCLUSIONES:">En una cohorte regional de veteranos con VIH, el 15% fueron evaluados formalmente por displasia anal. La enfermedad anal avanzada estuvo presente en el 33% de los examinados, el 5% de la poblaci&#xf3;n VIH +. Un fuerte predictor de enfermedad avanzada en esta cohorte es la relaci&#xf3;n CD4 / CD8, que es un marcador prometedor para estratificar las pr&#xe1;cticas de detecci&#xf3;n. La estratificaci&#xf3;n del riesgo usando CD4 / CD8 tiene el potencial de disminuir los ex&#xe1;menes invasivos onerosos para los pacientes de bajo riesgo e intensificar los ex&#xe1;menes para los de alto riesgo. Consulte <b>Video Resumen</b> en http://links.lww.com/DCR/Bxxx. <i>(Traducci&#xf3;n&#x2014; Dr. Francisco M. Abarca-Rendon)</i></AbstractText></OtherAbstract></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="entrez"><Year>2021</Year><Month>6</Month><Day>4</Day><Hour>12</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2021</Year><Month>6</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>10</Month><Day>15</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>7</Month><Day>1</Day></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">34086000</ArticleId><ArticleId IdType="mid">NIHMS1685823</ArticleId><ArticleId IdType="pmc">PMC8186795</ArticleId><ArticleId IdType="doi">10.1097/DCR.0000000000002009</ArticleId><ArticleId IdType="pii">00003453-202107000-00006</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Dandapani SV, Eaton M, Thomas CR Jr, Pagnini PG. HIV- positive anal cancer: an update for the clinician. J Gastrointest Oncol. 2010;1:34&#x2013;44.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3397564</ArticleId><ArticleId IdType="pubmed">22811803</ArticleId></ArticleIdList></Reference><Reference><Citation>Ryan DP, Compton CC, Mayer RJ. Carcinoma of the anal canal. N Engl J Med. 2000;342:792&#x2013;800.</Citation><ArticleIdList><ArticleId IdType="pubmed">10717015</ArticleId></ArticleIdList></Reference><Reference><Citation>Primary Care of Veterans with HIV. 2019. https://www.hiv.va.gov/pdf/pcm-manual.pdf.
Accessed
August 10, 2020.</Citation></Reference><Reference><Citation>Crawshaw BP, Russ AJ, Stein SL, et al. High-resolution anoscopy or expectant management for anal intraepithelial neoplasia for the prevention of anal cancer: is there really a difference? Dis Colon Rectum. 2015;58:53&#x2013;59.</Citation><ArticleIdList><ArticleId IdType="pubmed">25489694</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstone SE, Johnstone AA, Moshier EL. Long-term outcome of ablation of anal high-grade squamous intraepithelial lesions: recurrence and incidence of cancer. Dis Colon Rectum. 2014;57:316&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pubmed">24509453</ArticleId></ArticleIdList></Reference><Reference><Citation>Stewart DB, Gaertner WB, Glasgow SC, Herzig DO, Feingold D, Steele SR; Prepared on Behalf of the Clinical Practice Guidelines Committee of the American Society of Colon and Rectal Surgeons. The American Society of Colon and Rectal Surgeons Clinical Practice Guidelines for Anal Squamous Cell Cancers (Revised 2018). Dis Colon Rectum. 2018;61:755&#x2013;774.</Citation><ArticleIdList><ArticleId IdType="pubmed">29878949</ArticleId></ArticleIdList></Reference><Reference><Citation>Cajas-Monson LC, Ramamoorthy SL, Cosman BC. Expectant management of high-grade anal dysplasia in people with HIV: long-term Data. Dis Colon Rectum. 2018;61:1357&#x2013;1363.</Citation><ArticleIdList><ArticleId IdType="pubmed">30346366</ArticleId></ArticleIdList></Reference><Reference><Citation>Palefsky JM. Screening to prevent anal cancer: current thinking and future directions. Cancer Cytopathol. 2015;123:509&#x2013;510.</Citation><ArticleIdList><ArticleId IdType="pubmed">26237741</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomassi MJ, Abbas MA, Klaristenfeld DD. Expectant management surveillance for patients at risk for invasive squamous cell carcinoma of the anus: a large US healthcare system experience. Int J Colorectal Dis. 2019;34:47&#x2013;54.</Citation><ArticleIdList><ArticleId IdType="pubmed">30244347</ArticleId></ArticleIdList></Reference><Reference><Citation>Fazendin EA, Crean AJ, Fazendin JM, et al. Condyloma acuminatum, anal intraepithelial neoplasia, and anal cancer in the setting of HIV: do we really understand the risk? Dis Colon Rectum. 2017;60:1078&#x2013;1082.</Citation><ArticleIdList><ArticleId IdType="pubmed">28891852</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee GC, Kunitake H, Milch H, et al. What is the risk of anal carcinoma in patients with anal intraepithelial neoplasia III? Dis Colon Rectum. 2018;61:1350&#x2013;1356.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6219933</ArticleId><ArticleId IdType="pubmed">30303884</ArticleId></ArticleIdList></Reference><Reference><Citation>Leeds IL, Fang SH. Anal cancer and intraepithelial neoplasia screening: A review. World J Gastrointest Surg. 2016;8:41&#x2013;51.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4724586</ArticleId><ArticleId IdType="pubmed">26843912</ArticleId></ArticleIdList></Reference><Reference><Citation>Das D, Sarkar B, Mukhopadhyay S, Banerjee C, Biswas Mondal S. An altered ratio of CD4+ And CD8+ T lymphocytes in cervical cancer tissues and peripheral blood &#x2013; a prognostic clue? Asian Pac J Cancer Prev. 2018;19:471&#x2013;478.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5980936</ArticleId><ArticleId IdType="pubmed">29480666</ArticleId></ArticleIdList></Reference><Reference><Citation>Hema MN, Ferry T, Dupon M, et al.; ANRS CO 8 (APROCO/COPILOTE) study group. Low CD4/CD8 ratio is associated with non AIDS-defining cancers in patients on antiretroviral therapy: ANRS CO8 (Aproco/Copilote) prospective cohort study. PLoS One. 2016;11:e0161594.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4993515</ArticleId><ArticleId IdType="pubmed">27548257</ArticleId></ArticleIdList></Reference><Reference><Citation>Sigel K, Wisnivesky J, Crothers K, et al. Immunological and infectious risk factors for lung cancer in US veterans with HIV: a longitudinal cohort study. Lancet HIV. 2017;4:e67&#x2013;e73.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5444465</ArticleId><ArticleId IdType="pubmed">27916584</ArticleId></ArticleIdList></Reference><Reference><Citation>Tancini G, Barni S, Rescaldani R, Fiorelli G, Vivani S, Lissoni P. Analysis of T helper and suppressor lymphocyte subsets in relation to the clinical stage of solid neoplasms. Oncology. 1990;47:381&#x2013;384.</Citation><ArticleIdList><ArticleId IdType="pubmed">2145536</ArticleId></ArticleIdList></Reference><Reference><Citation>Tao CJ, Chen YY, Jiang F, et al. A prognostic model combining CD4/CD8 ratio and N stage predicts the risk of distant metastasis for patients with nasopharyngeal carcinoma treated by intensity modulated radiotherapy. Oncotarget. 2016;7:46653&#x2013;46661.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5216826</ArticleId><ArticleId IdType="pubmed">27270307</ArticleId></ArticleIdList></Reference><Reference><Citation>Geltzeiler CB, Xu Y, Carchman E, et al. CD4/CD8 ratio as a novel marker for increased risk of high-grade anal dysplasia and anal cancer in HIV+ patients: a retrospective cohort study. Dis Colon Rectum. 2020;63:1585&#x2013;1592.</Citation><ArticleIdList><ArticleId IdType="pubmed">33149020</ArticleId></ArticleIdList></Reference><Reference><Citation>Kramer JR, Hartman C, White DL, et al. Validation of HIV-infected cohort identification using automated clinical data in the Department of Veterans Affairs. HIV Med. 2019;20:567&#x2013;570.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6687524</ArticleId><ArticleId IdType="pubmed">31131549</ArticleId></ArticleIdList></Reference><Reference><Citation>Chaves EB, Folgierini H, Capp E, von Eye Corleta H. Prevalence of abnormal anal cytology in women infected with HIV. J Med Virol. 2012;84:1335&#x2013;1339.</Citation><ArticleIdList><ArticleId IdType="pubmed">22825810</ArticleId></ArticleIdList></Reference><Reference><Citation>Chiao EY, Giordano TP, Palefsky JM, Tyring S, El Serag H. Screening HIV-infected individuals for anal cancer precursor lesions: a systematic review. Clin Infect Dis. 2006;43:223&#x2013;233.</Citation><ArticleIdList><ArticleId IdType="pubmed">16779751</ArticleId></ArticleIdList></Reference><Reference><Citation>Goldstone SE, Winkler B, Ufford LJ, Alt E, Palefsky JM. High prevalence of anal squamous intraepithelial lesions and squamous-cell carcinoma in men who have sex with men as seen in a surgical practice. Dis Colon Rectum. 2001;44:690&#x2013;698.</Citation><ArticleIdList><ArticleId IdType="pubmed">11357031</ArticleId></ArticleIdList></Reference><Reference><Citation>Palefsky JM, Holly EA, Efirdc JT, et al. Anal intraepithelial neoplasia in the highly active antiretroviral therapy era among HIV-positive men who have sex with men. AIDS. 2005;19:1407&#x2013;1414.</Citation><ArticleIdList><ArticleId IdType="pubmed">16103772</ArticleId></ArticleIdList></Reference><Reference><Citation>Rosa-Cunha I, Degennaro VA, Hartmann R, et al. Description of a pilot anal pap smear screening program among individuals attending a Veteran&#x2019;s Affairs HIV clinic. AIDS Patient Care STDS. 2011;25:213&#x2013;219.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5206684</ArticleId><ArticleId IdType="pubmed">21366437</ArticleId></ArticleIdList></Reference><Reference><Citation>Chin-Hong PV, Palefsky JM. Natural history and clinical management of anal human papillomavirus disease in men and women infected with human immunodeficiency virus. Clin Infect Dis. 2002;35:1127&#x2013;1134.</Citation><ArticleIdList><ArticleId IdType="pubmed">12384848</ArticleId></ArticleIdList></Reference><Reference><Citation>Morency EG, Harbert T, Fatima N, Samolcyzk J, Maniar KP, Nayar R. Anal cytology: institutional statistics, correlation with histology, and development of multidisciplinary screening program with review of the current literature. Arch Pathol Lab Med. 2019;143:23&#x2013;29.</Citation><ArticleIdList><ArticleId IdType="pubmed">29652190</ArticleId></ArticleIdList></Reference><Reference><Citation>McBride JA, Striker R. Imbalance in the game of T cells: what can the CD4/CD8 T-cell ratio tell us about HIV and health? PLoS Pathog. 2017;13:e1006624.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5667733</ArticleId><ArticleId IdType="pubmed">29095912</ArticleId></ArticleIdList></Reference><Reference><Citation>Mutoh Y, Nishijima T, Inaba Y, et al. Incomplete recovery of CD4 cell count, CD4 percentage, and CD4/CD8 ratio in patients with human immunodeficiency virus infection and suppressed viremia during long-term antiretroviral therapy. Clin Infect Dis. 2018;67:927&#x2013;933.</Citation><ArticleIdList><ArticleId IdType="pubmed">29509894</ArticleId></ArticleIdList></Reference><Reference><Citation>Bertisch B, Franceschi S, Lise M, et al.; Swiss HIV Cohort Study Investigators. Risk factors for anal cancer in persons infected with HIV: a nested case-control study in the Swiss HIV Cohort Study. Am J Epidemiol. 2013;178:877&#x2013;884.</Citation><ArticleIdList><ArticleId IdType="pubmed">23900553</ArticleId></ArticleIdList></Reference><Reference><Citation>Gon&#xe7;alves JCN, Macedo ACL, Madeira K, et al. Accuracy of anal cytology for diagnostic of precursor lesions of anal cancer: systematic review and meta-analysis. Dis Colon Rectum. 2019;62:112&#x2013;120.</Citation><ArticleIdList><ArticleId IdType="pubmed">30451747</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>